RESEARCH POSTER PRESENTATIONS SESSION I: MONDAY, MAY 23, 2011

Click on the topic below to view posters

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 23, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 23, 2011 - 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 23, 2011 - 6:30PM – 7:30PM
DISMANTLE: Monday, May 23, 2011 - 8:30PM – 9:00PM

Health Care Use & Policy Studies – Consumer Role in Health Care

PHP1

USE OF STRUCTURAL EQUATION MODELING TO EXPLAIN CONSUMER BEHAVIOR TOWARDS GENERIC DRUG DISCOUNT PROGRAMS

 

Patel HK, Sansgiry S
University of Houston, Houston, TX, USA

PHP2

TRENDS IN AND PREDICTORS OF DISCOUNT GENERIC MEDICATION PROGRAM UTILIZATION

 

Gatwood J, Tungol A, Truong C, Erickson S
University of Michigan, Ann Arbor, MI, USA

PHP3

FEDERAL ENFORCEMENT ACTIONS AGAINST FRAUD AND ABUSE BY PHARMACEUTICAL MANUFACTURERS: 1996- 2010

 

Qureshi Z1, Sartor O2, Bennett C1
1University of South Carolina, Columbia, SC, USA, 2Tulane University, New Orleans, LA, USA

PHP4

WHEN STAKEHOLDERS DON'T AGREE: DISCREPANCIES IN MAB “APPROVALS” OVER THE PAST TEN YEARS

 

Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA

PHP5

INCENTIVE-BASED INTERVENTIONS – REWARDING PATIENTS FOR GOOD BEHAVIOUR

 

Haynes S, Costello S, Brooks-Rooney C, Hamer N
Costello Medical Consulting Ltd, Cambridge, UK

Health Care Use & Policy Studies – Diagnosis Related Group

PHP6

EXPLORE THE USE OF DRUGS IN MEDICAL INSURANCE BILLING IN CHINA

 

Tan Z
Ministry of Labor and Social Security, Beijing, China

Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy

PHP7

DEVELOPING PUBLIC HEALTH GUIDANCE - WHAT ARE THE DATA GAPS? REVIEW OF THE GAPS IN THE EVIDENCE IDENTIFIED BY NICE IN THE UK

 

Kusel J, Costello S, Hamer N, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK

PHP8

PHYSICIAN SHORTAGE IMPACT ON PATIENT RX USE FOR SELECT CHRONIC CONDITIONS

 

Dall T1, Seiders M2, Price P2, Chakrabarti R1, Tal S1, Kowal S1, Larson J1
1IHS, Washington, DC, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PHP9

IMPACT OF FREE PRESCRIPTIONS IN WALES ON PRESCRIBING - A THIN DATABASE STUDY

 

Thompson M, Sedani T, Blak BT, Hards M
Cegedim Strategic Data Medical Research Ltd, London, UK

PHP10

THE TEMPORAL ASSOCIATION BETWEEN PRESCRIBED OPIOIDS AND THE NATIONAL DEATH RATE DUE TO OPIOID POISONING

 

Gokhale MN, Martin B
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PHP11

REVIEW OF ADJUSTMENT OF ESSENTIAL MEDICINE LIST AT PROVINCIAL LEVEL IN CHINA

 

Shi LW1, Ma YQ2, Xu LP2, Zhao DH2, Zhang Y2
1Peking University, Beijing, China, 2AstraZeneca (WUXI) Trading CO., Ltd, Shanghai, China

PHP12

WITHDRAWN

 

 

PHP13

THE IMPACT OF A QUALITY IMPROVEMENT INITIATIVE ON INAPPROPRIATE MEDICATION USE IN THE OUTPATIENT ELDERLY

 

Dudash K1, Templin M1, Keith SW1, Del Canale S2, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Local Health Authority Parma, Parma, Italy

PHP14

THE EFFECTS OF PHARMACEUTICAL COST CONTAINMENT ON ACCESS TO LICENSED AND SUBSIDIZED MEDICINES UNDER SINGLE PAYER SYSTEMS IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA AND NEW ZEALAND

 

Ragupathy R1, Aaltonen K2, Tordoff J1, Norris P1, Reith D1
1University of Otago, Dunedin, New Zealand, 2University of Eastern Finland, Kuopio, Finland

PHP15

ISSUES ASSOCIATED WITH BIOLOGIC AGENTS: HEALTHCARE STAKEHOLDER SURVEY

 

Toscani M1, Vogenberg R1, Nash D1, Peskin S2
1Jefferson School of Population Health, Philadelphia, PA, USA, 2Medi Media, Yardley, PA, USA

PHP16

ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING SPECTRAL GRAPH THEORY

 

Lindgren P1, Åkerborg Ö2
1i3 Innovus, San Diego, CA, USA, 2i3 Innovus, Stockholm, Sweden

PHP17

PRESCRIPTION DRUG MONITORING PROGRAMS: THE PATIENT PERSPECTIVE

 

Goodin A, Blumenschein K, Freeman PR, Talbert J
University of Kentucky, Lexington, KY, USA

PHP18

WITHDRAWN

 

 

PHP19

TRENDS IN ON-LABEL AND OFF-LABEL PRESCRIBING OF MONTELUKAST IN A COMMERCIALLY INSURED POPULATION 1998-2008

 

Ali MM, Martin B
University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

PHP20

MEDICATION USE SURVEY OF INPATIENTS WITH BASIC MEDICAL INSURANCE (2010)

 

Xiong X
China Health Insurance Research Association, Beijing, China

PHP21

WITHDRAWN

 

 

PHP22

ASSOCIATION OF SELF-REPORTED HEALTH STATUS WITH COST-RELATED MEDICATION NONADHERENCE AND OUT-OF-POCKET PHARMACY SPENDING AMONG SENIOR MEDICARE BENEFICIARIES

 

Tang Y
University of Pittsburgh, Pittsburgh, PA, USA

PHP23

THE IMPACT OF MEDICARE PART D ON PRESCRIPTION VOLUME AND OUT-OF-POCKET COSTS OF MEDICALLY NECESSARY DRUGS

 

Sepulveda B, Doyle J, White C
Quintiles, Hawthorne, NY, USA

PHP24

NUMBER AND TYPE OF DRUGS USED BY SENIORS ON PUBLIC DRUG PROGRAMS IN CANADA, 2002 TO 2008

 

Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada

PHP25

THE POTENTIAL VALUE OF THE 2014 MEDICAID EXPANSION

 

Sepulveda B, Doyle J
Quintiles, Hawthorne, NY, USA

PHP26

ANALYSIS OF THE SIX PROTECTED MEDICATION CLASSES BASED ON PLAN TYPE AND LOW INCOME SUBSIDY STATUS

 

Blackwell S, Waldron C, Evans M
Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA

PHP27

CANADIAN PUBLIC DRUG PROGRAM SPENDING ON SENIORS, 2002 TO 2008

 

Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada

PHP28

COMPLIANCE WITH TREATMENT GUIDELINE RECOMMENDATIONS: USE OF OVER-THE-COUNTER MEDICATIONS IN PATIENTS RECEIVING BISPHOSPHONATES, ANTIEPILEPTICS, OR CHRONIC OPIOIDS

 

Barnes KD, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

Health Care Use & Policy Studies – Equity and Access

PHP29

WITHDRAWN

 

 

PHP30

CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH PRICED DRUGS?

 

Anastasaki E, Colasante W, Imbeah-Ampiah R
PriceSpective Ltd., London, UK

PHP31

REVIEW OF HIGHLY SPECIALIZED MEDICAL SERVICES IN KAZKAHSTAN WITHIN AN INTRODUCTIN OF UNIFIED NATIONAL HEALTH SYSTEM

 

Yergaliyev K, Issayeva R, Umralin T
Ministry of Health of Republic of Kazakhstan, Astana, Kazakhstan

Health Care Use & Policy Studies – Formulary Development

PHP32

ANALYSIS OF PHARMACISTS' INTERVENTIONS ON ELECTRONIC VERSUS TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES

 

Gilligan A, Miller K, Mohney A, Montenegro C, Schwarz J, Warholak TL
University of Arizona, Tucson, AZ, USA

PHP33

IMPACT OF PHARMACY AND MEDICAL PLAN INTEGRATION ON OVERALL MEDICAL COSTS

 

Bunz TJ, Nguyen HV, Regine ML
CIGNA HealthCare, Bloomfield, CT, USA

PHP34

WITHDRAWN

 

 

PHP35

DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT: THE GOOD, THE BAD, AND THE FUTURE

 

Machado M1, Fonseca E2, Fonseca M3
1GlaxoSmithKline Brazil, Rio de Janeiro, Brazil, 2Federal University of São Paulo, São Paulo, Brazil, 3Axia.Bio, São Paulo, Brazil

Health Care Use & Policy Studies – Health Care Costs & Management

PHP36

CATASTROPHIC INJURY-RELATED ENROLLMENT AND COSTS IN A STATE MEDICAID FEE-FOR-SERVICE PROGRAM

 

Smith MJ1, Zaloshnja E2, Miller TR2
1University of Oklahoma, Tulsa, OK, USA, 2Pacific Institute for Research & Evaluation, Columbia, MD, USA

PHP37

A REGISTRY PERSPECTIVE OF OF HOSPITAL DISCHARGE COSTS: PILOT RESULTS OF THE 10 MOST FREQUENT DIAGNOSIS AND PROCEDURES OF THE ARGENTINE-HEALTH CARE COST AND UTILIZATION PROJECT (A-HCUP)

 

Insua JT1, Giunta D2, Ioli P3, Villalon R1
1Hospital Universitario Austral, Universidad Austral, Derqui, Argentina, 2Hospital Italiando de Buenos Aires, Caba, Argentina, 3Hospital Privado de la Comunidad, Fundacion Medica de Mar del Plata, Mar del Plata, Buenos Aires, Argentina

PHP38

UTILIZATION, PRICE AND SPENDING OF ANTI-TUMOR NECROSIS FACTOR BIOLOGICS IN THE UNITED STATES MEDICAID PROGRAM

 

Atzinger C, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PHP39

WITHDRAWN

 

 

PHP40

HEALTH CARE REFORMS UNDER ECONOMIC CRISIS: THE GREEK CASE

 

Kritikou P, Latsou D, Yfantopoulos J
National and Kapodistrian University of Athens, Athens, Greece

PHP41

THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND UNITED STATES

 

McConkey D
Double Helix Consulting, London, UK

PHP42

EVALUATING DRUG COST AND RESTRICTION PROCESSES OF COMMONLY USED PRESCRIPTION DRUGS UNDER EACH 2011 CALIFORNIA STAND-ALONE MEDICARE PART D PLAN

 

Patel R, Kim MJ, Walberg M, Woelfel J
University of the Pacific, Stockton, CA, USA

PHP43

THE INFLUENCE OF PATIENT ACCESS SCHEMES ON APPRAISAL DECISIONS BY NICE IN THE UK

 

Timm B, Kusel J, Hamer N, Costello S
Costello Medical Consulting Ltd, Cambridge, UK

PHP44

DURATION OF PATIENTS VISITS TO THE EMERGENCY DEPARTMENT

 

Karaca Z, Wong H, Mutter R
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

PHP45

TRENDS OF HEALTH CARE UTILIZATION AMONG LOYAL PATIENTS IN A MEDICAL CENTER UNDER TAIWAN'S UNIVERSAL HEALTH INSURANCE PROGRAM

 

Lin HW1, Yu IW2, Chang CK2, Lin CC1, Wu HC2, Hung JS2
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, Taiwan

PHP46

THE STATE OF HEALTH ECONOMIC EVALUATION IN SOUTH AFRICA: A SYSTEMATIC REVIEW

 

Gavaza P1, Rascati KL2, Oladapo AO2, Khoza S2
1Appalachian College of Pharmacy, Oakwood, VA, USA, 2University of Texas at Austin, Austin, TX, USA

PHP47

ADVERSE DRUG EVENTS AND ELECTRONIC MEDICAL RECORDS: RESULTS FROM THE 2007-2008 NATIONAL AMBULATORY MEDICAL CARE SURVEY

 

Hogg JM, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

PHP48

STATUS OF PHARMACIST AT COMMUNITY LEVEL: AN EXPLORATORY STUDY IN QUETTA, PAKISTAN

 

Saleem F1, Al-Qazaz HK1, Azhar S1, Ahmad N1, Atif M1, Haq N1, Asif M2, Iqbal Q3
1Universiti Sains Malaysia (USM), Pinang, Penang, Malaysia, 2The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan, 3University of Balochistan, Quetta, Balochistan, Pakistan

PHP49

UTILIZATION AND COST OF THE HEALTH PLAN - EFFECTS OF SPOUSAL BEREAVEMENT

 

Reis Neto J1, Arantes ACL2
1CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil, 2CASA DO CUIDAR, Sao Paulo, SP, Brazil

PHP50

MIXED EVIDENCE FOR THE "HEALTHY ADHERER EFFECT" IN A SAMPLE OF 22,070 ADULTS WITH CHRONIC DISEASE IN UNITED STATES

 

McHorney C, Gadkari A
Merck & Co., Inc, North Wales, PA, USA

PHP51

MORTALITY AFTER SPOUSAL BEREAVEMENT IN BENEFICIARIES OF THE HEALTH PLAN

 

Reis Neto J, Arantes ACL
CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil

PHP52

INCREASE IN UNINTENTIONAL FATAL POISONINGS BY NOXIOUS SUBSTANCES IN KANSAS CITY, MISSOURI, FROM 1999 TO 2008

 

Liu Y1, Cai J2, Hong L3, Hoff GL2, Okah FA1
1The University of Missouri – Kansas City, Kansas City, MO, USA, 2Kansas City Health Department, Kansas City, MO, USA, 3The University of Tennessee, Memphis, TN, USA

PHP53

A RAPID EVALUATION UNIT INCREASES EMERGENCY DEPARTMENT VISITS

 

Twanmoh J1, Fleming AE2, Brooks D3, Jiang Y4, Villacorta R4, McCombs J4
1St. Agnes Hospital, Baltimore, MD, USA, 2Johns Hopkins University, Baltimore, MD, USA, 3Johns Hopkins Medicine, Baltimore, MD, USA, 4USC School of Pharmacy, Los Angeles, CA, USA

PHP54

THE IMPACT OF PHARMACIST-CONDUCTED MEDICATION RECONCILIATION WITH PATIENT COUNSELING AT HOSPITAL ADMISSION

 

Chen CC1, Huang YF1, Ho SW2, Lu SH2, Lin HY2, Liu HP1
1Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan

PHP55

THE INFLUENCE OF COST-EFFECTIVENESS ISSUES OF THE APPRAISED ORPHAN DRUGS ON RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL)

 

Ofierska-Sujkowska G, Jagodzinska-Kalinowska K, Matusewicz W
Agency for Health Technology Assessment in Poland, Warsaw, Poland

PHP56

DEMONSTRATING CLINICAL-EFFECTIVENESS USING INDIRECT AND MIXED TREATMENT COMPARISON ANALYSIS: A REVIEW OF MANUFACTURERS' SINGLE TECHNOLOGY APPRAISAL (STA) SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

 

Bending MW1, Hutton J1, McGrath C2
1University of York, York Health Economics Consortium, York, UK, 2Pfizer, Surrey, UK

PHP57

PATTERNS OF INSURANCE COVERAGE IN THE UNITED STATES: ANALYSIS OF THE 2004-2007 MEDICAL EXPENDITURE PANEL SURVEYS (MEPS)

 

Berry E1, Kelton CM1, Heaton PC1, Guo JJ2, Fairbrother G3, Hanseman D2
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, Cincinnati, OH, USA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

PHP58

WITHDRAWN

 

 

PHP59

THE AVAILABILITY AND SIGNIFICANCE OF COST-EFFECTIVENESS DATA FOR INFORMING DECISIONS TO ADD NEW DRUGS TO THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL

 

Greenberg D1, Wacht O1, Siebzehner MI2
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2The Israeli Center for Technology Assessment in Health Care, Tel Hashomer, Israel

PHP60

ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING AND MARKET ACCESS

 

Grosvenor A, Saraf S, Jones K
PriceSpective Ltd., London, UK

PHP61

WIDER CONSULTATION IN HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS: BETTER UNDERSTANDING OR A LOBBYING OPPORTUNITY?

 

Bending MW1, Hutton J1, McGrath C2
1University of York, York Health Economics Consortium, York, UK, 2Pfizer, Surrey, UK

PHP62

WHAT IS THE IMPACT OF COMPARATIVE EFFECTIVENESS AND VALUE BASED PRICING ON A PRODUCT'S VALUE AND MARKET ACCESS?

 

Walker R, Ng-Haing J, Koruth R, Sparrowhawk K
PriceSpective, London, UK

PHP63

WHAT INFLUENCES PHARMACEUTICAL REIMBURSEMENT DECISIONS? A SYSTEMATIC REVIEW OF FACTORS REPORTED TO INFLUENCE DECISIONS IN OECD COUNTRIES

 

Bending MW1, Hutton J1, McGrath C2, Glanville J1
1University of York, York Health Economics Consortium, York, UK, 2Pfizer, Surrey, UK

PHP64

THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM

 

Mauskopf J1, Chirila C1, Masaquel C1, Boye KS2, Bowman L2, Birt J2, Grainger D3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly and Company, Sydney, Australia

PHP65

HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR CELLULAR THERAPIES AND REGENERATIVE MEDICINES: LESSONS FROM A HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT ANALYSIS IN THE UNITED STATES

 

Faulkner EC, Spinner DS
RTI Health Solutions, Research Triangle Park, NC, USA

PHP66

DEMONSTRATING “DISEASE MODIFYING THERAPIES”? AN HTA PERSPECTIVE

 

McDonald P, Colasante W, Oshinowo B, Saraf S
PriceSpective Ltd., London, UK

PHP67

UNDERSTANDING THE VIETNAMESE PRICING AND REIMBURSEMENT ENVIRONMENT THROUGH A COMPARISON WITH THAT OF CHINA

 

Lewis S, Dummett H
Double Helix Consulting, London, UK

PHP68

THE 15 YEARS EXPERIENCE OF NEW DRUGS ADOPTION AND REIMBURSEMENT IN TAIWAN'S NATIONAL HEALTH INSURANCE

 

Huang WF1, Hsieh CF1, Chen GT2
1National Yang-Ming University, Taipei, Taiwan, 2Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

Health Care Use & Policy Studies – Health Care Research & Education

PHP69

HOW MUCH FOR A QALY IN KOREA

 

Kim Y1, Shin S1, Park S1, Song H1, Park J1, Bae E2, Ahn J1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Sangji University, Wonju, Kangwon-do, South Korea

PHP70

PREVENTABLE HOSPITALIZATIONS AND HEALTH INSURANCE COVERAGE IN HARRIS COUNTY, TEXAS

 

Murty S, Begley CE, Swint JM
University of Texas Health Science Center at Houston, Houston, TX, USA

PHP71

IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE

 

Naik R1, Borrego M2, Dodd M2, Raisch D2, Khan N3, Bakhireva L2, Gupchup G4, Cunico L2
1Allergan, Inc., Irvine, CA, USA, 2University of New Mexico, Albuquerque, NM, USA, 3Oxford Outcomes Ltd., Morristown, NJ, USA, 4Southern Illinois University Edwardsville, Edwardsville, IL, USA

PHP72

ASSESSING THE QUALITY OF PHARMACOECONOMIC STUDIES IN INDIA: A SYSTEMATIC REVIEW

 

Desai P1, Chandwani H1, Rascati K2
1University of Texas at Austin, Austin, TX, USA, 2University of Texas, College of Pharmacy, Austin, TX, USA

PHP73

SYSTEMATIC LITERATURE REVIEW ON HETEROGENEITY OF RELATIVE EFFECTIVENESS AND RELATIVE EFFICACY OF MEDICINES IN EUROPE

 

Puig-Peiró R, Towse A, Mestre-Ferrandiz J
Office of Health Economics, London, UK

PHP74

CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS: CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION

 

Spinner DS1, Walter JW1, Vazquez-Gragg M1, Bloise T1, Stafford-Smith M2, Faulkner EC1, Taekman JM2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Duke University Medical Center, Durham, NC, USA

PHP75

USE OF ELECTRONIC MEDICAL RECORDS FROM 2001 THROUGH 2010: IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH

 

Anastassopoulos KP1, Mann R2, Knight TG1, Sudharshan L1, Ackerman SJ2
1Covance Market Access Services, Inc., Gaithersburg, MD, USA, 2Covance Market Access Services, Inc., San Diego, CA, USA

PHP76

THE OUTLOOK OF LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH: AN APPLICATION OF THE PRECIS FRAMEWORK

 

Vincent L
Quintiles Global Consulting, Hawthorne, NY, USA

PHP77

THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS RESEARCH IN RUSSIA: A SYSTEMATIC REVIEW

 

Gavaza P1, Shepherd MD2, Shcherbakova N3, Khoza S3
1Appalachian College of Pharmacy, Oakwood, VA, USA, 2Center for Pharmacoeconomic Studies, College of Pharmacy, University of Texas at Austin, Austin, TX, USA, 3Division of Pharmacy Administration, College of Pharmacy, University of Texas at Austin, Austin, TX, USA

PHP78

CHARACTERISTICS OF HOMELESS INDIVIDUALS USING INPATIENT AND EMERGENCY DEPARTMENT SERVICES

 

Karaca Z, Wong H, Mutter R
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

PHP79

ROLE OF HTA SYSTEMS IN REIMBURSEMENT AND MARKET ACCESS: COMPARISON OF TURKEY AND POLAND

 

Kirpekar S, Shankland B, Dummett H
Double Helix Consulting, London, UK

PHP80

RELATIONSHIP OF HERBAL KNOWLEDGE TOWARDS ATTITUDE FORMATION AMONG FUTURE PHARMACISTS

 

Sura SD, Chabria A, Sansgiry S
University of Houston, Houston, TX, USA

PHP81

CAREGIVER WELL-BEING AND HEALTH CARE ACCESS AND QUALITY AMONG CHILDREN WITH CHRONIC PHYSICAL AND MENTAL CONDITIONS

 

Rane P, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PHP82

THE IMPACT OF INTEGRATED MEDICAL CARE SERVICES FOR LOYAL PATIENTS IN A 2000-BED MEDICAL CENTER UNDER TAIWAN'S UNIVERSAL HEALTH INSURANCE PROGRAM

 

Lin HW1, Yu IW2, Lin CH2, Chang CK2, Chang LY2, Hsieh YW2, Wu HC2, Lin CC1, Hung JS2, Cho DY2
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, Taiwan

Health Care Use & Policy Studies – Health Technology Assessment Programs

PHP83

HTA DECISION DRIVERS FOR ACCEPTANCE OF HIGH ICER SUBMISSIONS AND REJECTION OF LOW ICER SUBMISSIONS

 

Ternouth AM1, Jakel A2, Plested M1, Modha R1
1HERON Evidence Development Ltd, Luton, UK, 2HERON Evidence Development Ltd, Stopsley, UK

PHP84

AHRQ VERSUS NICE: DO THE CONCLUSIONS IN CER REPORTS CORRESPOND CLOSELY TO THE COMPARATIVE EFFECTIVENESS ASSESSMENTS MADE IN HTA REPORTS?

 

Alnwick K
HERON Evidence Development Ltd, London, UK

PHP85

APPLYING FUZZY MULTIPLE CRITERIA DECISION MAKING TO ESTABLISH A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM WITH COVERAGE IMPLICATIONS IN TAIWAN NATIONAL HEALTH INSURANCE

 

Lin CW
I-Shou University, Kaohsiung, Taiwan

Health Care Use & Policy Studies – Population Health

PHP86

IRRATIONAL USE OF ANTIBIOTICS AND ROLE OF PHARMACISTS: AN INSIGHT FROM A QUALITATIVE STUDY IN NEW DELHI, INDIA

 

Kotwani A1, Wattal C2, Joshi PC3, Holloway K4
1V. P. Chest Institute, University of Delhi, Delhi, India, 2Sir Ganga Ram Hospital, New Delhi, India, 3Delhi University, Delhi, India, 4World Health Organization, New Delhi, India

Health Care Use & Policy Studies – Prescribing Behavior & Treatment Guidelines

PHP87

IMPACT OF PRESCRIPTION MONITORING PROGRAMS ON CONTROLLED SUBSTANCE PRESCRIBING BEHAVIOR

 

Freeman PR1, Talbert J2, Blumenschein K1
1University of Kentucky, Lexington, KY, USA, 2University of Kentucky College of Pharmacy, Lexington, KY, USA

PHP88

INFLUENCE OF HOSPITAL CHOICES OF DRUGS ON THE PHARMACEUTICAL CONSUMPTION IN THE COMMUNITY

 

Gallini A1, Legal R2, Taboulet F1
1University of Toulouse - INSERM 1027, Toulouse, France, 2French Department of Health, Paris, France

PHP89

THE IMPLEMENTATION OF PUBLIC HEALTH GUIDANCE: PREFERENCE FOR CLINICAL OVER BEHAVIOURAL INTERVENTIONS

 

Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S
Costello Medical Consulting Ltd, Cambridge, UK

PHP90

TRENDS IN UTILIZATION OF PREGNANCY RISK CATEGORY D AND X DRUGS AMONG PREGNANT WOMEN IN UNITED STATES

 

Shah AJ, Patil DS, Kadakia A, Aparasu RR
University of Houston, Houston, TX, USA

Health Care Use & Policy Studies – Quality of Care

PHP91

ASSOCIATION BETWEEN QUALITY OF CARE AND SHORT TERM OUTCOMES FOR VERY OLD PATIENTS HOSPITALIZED FOR ACUTE ILLNESSES

 

Chong WF1, Ding YY2, Sun Y1, Heng BH1
1National Healthcare Group, Singapore, 2Tan Tock Seng Hospital, Singapore

PHP92

RESULTS OF A PHARMACY MANAGEMENT PROGRAM FOR IMPROVING MEDICATION ADHERENCE

 

Regine ML, Bunz TJ
CIGNA HealthCare, Bloomfield, CT, USA

PHP93

AN EXAMINATION OF HOSPITAL-ACQUIRED CONDITIONS BY AGE AND PAYER IN FIFTEEN STATES, 2008

 

Maeda JL1, Parlato J2, Levit K1, Andrews RM3, Jiang HJ3
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Cambridge, MA, USA, 3Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

Health Care Use & Policy Studies – Regulation of Health Care Sector

PHP94

THE ROLE OF HEALTH-RELATED QUALITY OF LIFE DATA IN THE DRUG APPROVAL PROCESSES IN THE UNITED STATES AND EUROPE: A REVIEW OF GUIDANCE DOCUMENTS AND AUTHORIZATIONS OF MEDICINAL PRODUCTS FROM 2006 TO 2010

 

Marquis P1, Caron M2, Emery MP2, Scott J3, Acquadro C2
1MAPI Values, Boston, MA, USA, 2MAPI Research Trust, Lyon, France, 3MAPI Values, Macclesfield, UK

PHP95

EXPECTED CHANGES IN HEALTH CARE UTILIZATION DUE TO PATIENT PROTECTION AND AFFORDABLE CARE ACT

 

Ghushchyan VH1, Sullivan PW2, Naim A3, Nair KV1
1University of Colorado, Denver, Aurora, CO, USA, 2Regis University School of Pharmacy, Denver, CO, USA, 3Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PHP96

REASONS FOR REJECTION OF PRO LABEL CLAIMS: AN ANALYSIS BASED ON A REVIEW OF PRO USE AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010

 

DeMuro C1, Clark M2, Mordin M2, Evans E1, Copley-Merriman K2, Fehnel SE1, Gnanasakthy A3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Ann Arbor, MI, USA, 3Novartis, East Hanover, NJ, USA

PHP97

PRO LABEL CLAIMS: AN ANALYSIS BASED ON A REVIEW OF PROS AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010

 

Mordin M1, Clark M1, DeMuro C2, Evans E2, Copley-Merriman K1, Fehnel S2, Gnanasakthy A3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

PHP98

A TREND ANALYSIS OF NEW MOLECULAR ENTITIES WITHDRAWN FOR SAFETY REASONS FROM 1980 TO 2009 IN THE UNITED STATES

 

Seoane-Vazquez E1, Rodriguez-Monguio R2, Qureshi ZP3, Szeinbach SL4
1Massachusetts College of Pharmacy & Health Sciences, Boston, MA, USA, 2University of Massachusetts, Amherst,, MA, USA, 3University of South Carolina, Columbia, SC, USA, 4Ohio State University, Columbus, OH, USA

PHP99

WILL BIOPHARMACEUTICAL INNOVATION STILL BE A PICTURE OF HEALTH AFTER IMPLEMENTATION OF HEALTH CARE REFORM?

 

Ross KD
University of Washington, Seattle, WA, USA

PHP100

PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA

 

Kumar J, Bachman EM
HERON Evidence Development LLC, Somerville, NJ, USA

Health Care Use & Policy Studies – Risk Sharing/Performance-Based Agreements

PHP101

VALUE BASED PRICING: WHAT IS THE FUTURE FOR PATIENT ACCESS SCHEMES?

 

Loveman CM, Mallinson M, Areteou T, White R
Double Helix Consulting, London, UK

PHP102

WHICH CRITERIA ARE USED IN HEALTH CARE DECISIONMAKING AND PRIORITY SETTING? A LITERATURE REVIEW FOR AN INTERNATIONAL SURVEY OF DECISIONMAKERS

 

Guindo LA1, Wagner M2, Baltussen R3, Rindress D2, Van Til J4, Kind P5, Goetghebeur M2
1MSc Candidate, Montreal, QC, Canada, 2BioMedCom Consultants Inc., Dorval, QC, Canada, 3Radboud University, Nijmegen, The Netherlands, 4University of Twente, Enschede, The Netherlands, 5University of York, York, UK

PHP103

COMPARATIVE EFFECTIVENESS REVIEWS AND THEIR POTENTIAL IMPACT ON FORMULARY ACCESS IN THE UNITED STATES

 

Xia AD
HERON Evidence Development Ltd, London, UK

PHP104

CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114

 

Lin PJ1, Hughes TE2, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2i3 Innovus, Carmel, IN, USA

PHP105

HOW ARE COVERAGE DECISIONS MADE IN PUBLICLY FUNDED HEALTH CARE PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES?

 

Hornberger J, Shewade A, Gutierrez H
Cedar Associates LLC, Menlo Park, CA, USA

Health Care Use & Policy Studies – Conceptual Papers

PHP106

DISPARITY IN ACCESS TO NOVEL DIABETIC AGENTS FOR MEDICARE PART D ELDERLY COMPARED TO COMMERCIAL INSURED PATIENTS: INSIGHT INTO DOWNSTREAM EFFECTS OF CMS FORMULARY COVERAGE GUIDELINES FOR PDP'S

 

Schwartz EL1, Davis EA1, Belazi D2, Hasan S2
1PriceSpective, San Diego, CA, USA, 2Wolters Kluwer Pharma Solutions, Yardley, PA, USA

PHP107

BIOMARKERS: A CHANGING PARADIGM FOR DEVELOPMENT

 

Pardini AT, Saraf S, Sparrowhawk K

PriceSpective Ltd., London, UK

PHP108

THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION OF PRICING BODIES: LESSONS LEARNED FROM BRAZIL AND CANADA, IMPLICATIONS FOR THE UNITED STATES

 

Cost P, Snyder T, Zaidi Q
HERON Evidence Development LLC, Somerville, NJ, USA

PHP109

AN OUTCOMES PROFILE REGISTRY FOR ESTABLISHING A BASELINE MATRIX IN COMPARATIVE EFFECTIVENESS STUDIES IN PREDICTIVE PHARMACOLOGY

 

Wheeler C
NTELX, Inc, Vienna, VA, USA

PHP110

BIOSIMILARS LITERATURE REVIEW: THE CURRENT LANDSCAPE AND IMPLICATIONS OF RECENT HEALTHCARE LEGISLATION FOR THE UNITED STATES MARKET

 

Maiese BA, Lee EH, Toscani MT
Jefferson School of Population Health, Philadelphia, PA, USA

PHP111

OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA: IMPLICATIONS FOR NOVEL THERAPEUTICS

 

Fleming M, Martin CR
University of the West of Scotland, Ayr, UK

PHP112

DEFINITIONAL CRITERIA FOR CHRONIC FATIGUE SYNDROME: A CRITICAL REVIEW

 

Christley Y, Duffy T, Martin CR
University of the West of Scotland, Ayr, UK

PHP113

IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA AGENCY: TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL APPRAISAL

 

Green MJ
HERON Evidence Development LLC, Somerville, NJ, USA

PHP114

OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE

 

Benson J, Enterline L
Bristol-Myers Squibb, Plainsboro, NJ, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 23, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 23, 2011 - 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 23, 2011 - 6:30PM – 7:30PM
DISMANTLE: Monday, May 23, 2011 - 8:30PM – 9:00PM

Cardiovascular Disorders – Clinical Outcomes Studies

PCV1

DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY IMPACT RISK OF VENOUS THROMBOEMBOLISM: ESTRADIOL TRANSDERMAL SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY

 

Laliberté F1, Dea K1, Duh MS2, Kahler KH3, Rolli M3, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCV2

THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS

 

Chang JY1, Nichol MB2
1University of Southern California, Alhambra, CA, USA, 2University of Southern California, Los Angeles, CA, USA

PCV3

RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES: A CLAIMS DATA ANALYSIS

 

Dharmarajan SH, Yang Y, Athavale AS, Bentley JP, Null KD, Banahan BF
University of Mississippi, University, MS, USA

PCV4

TREATMENT PATTERNS, CLINICAL AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN ABDOMINAL SURGERY PATIENTS

 

Wang L, Dysinger AH, Du J, Xie L, Baser O
STATinMED Research, Ann Arbor, MI, USA

PCV5

PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THEUNITED STATES MEDICARE POPULATION

 

Baser O1, Verpillat P2, Wang L1
1STATinMED Research, Ann Arbor, MI, USA, 2Sanofi-Aventis Group, Paris, France

PCV6

ANALYSIS OF MYOCARDIAL INFARCTION RELATED CLINICAL OUTCOMES, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

 

Wang L, Xie L, Baser O
STATinMED Research, Ann Arbor, MI, USA

PCV7

ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED MEDICALLY ILL PATIENTS

 

Baser O, Xie L, Du J, Wang L
STATinMED Research, Ann Arbor, MI, USA

PCV8

EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS POPULATION

 

Yi T, Tran JN, Bounthavong M
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA

PCV9

WITHDRAWN

 

 

PCV10

THE EFFECT OF INTERACTIONS BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS ON ADVERSE CARDIOVASCULAR OUTCOMES IN COMMERCIALLY INSURED PATIENTS WITH ACUTE CORONARY SYNDROME

 

Bhurke S, Martin B, Li C, Franks A, Bursac Z, Said Q
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PCV11

PNEUMONIA AFTER ACUTE ISCHEMIC STROKE: PREVALENCE, ASSOCIATED FACTORS AND OUTCOMES

 

Al-Jabi SW1, Hassan Y1, Abd Aziz N1, Looi I2, Zyoud SH1
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2Pulau Pinang Hospital, Pinang, Malaysia

PCV12

IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) ON HEALTH OUTCOMES AND COST TO MEDICAID: THE MONETARY BENFITS OF QUALITY HEALTH CARE

 

Athavale AS, Banahan BFI, Mendonca CM
University of Mississippi, University, MS, USA

PCV13

BURDEN OF COMORBIDITIES AMONG PATIENTS WITH ATRIAL FIBRILLATION

 

LaMori JC1, Gross HJ2, Patel AA1, Crain M3, DiBonaventura MD2, Mody SH1, Schein J1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, New York, NY, USA, 3Centocor Ortho Biotech Services, LLC, Virginia Beach, VA, USA

PCV14

DYSPEPSIA AND DISEASE BURDEN AMONG PATIENTS WITH ATRIAL FIBRILLATION (AF)

 

LaMori JC1, Gross HJ2, Patel AA1, Crain M3, DiBonaventura MD2, Mody SH1, Schein J1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, New York, NY, USA, 3Centocor Ortho Biotech Services, LLC, Virginia Beach, VA, USA

PCV15

PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND HYPERTENSION - A NHANES 2007-2008 STUDY

 

Bhounsule P, Abughosh S
University of Houston, Houston, TX, USA

PCV16

MANAGING GROWING POPULATION OF TYPE-2 DIABETES FROM COMMUNITY TO TEACHING HOSPITALS IN CHINA

 

Zhang D1, Ji L2, Hu D2
1VitalStrategic Research Institute, Berwyn, PA, USA, 2Peking University People's Hospital, Beijing, China

PCV17

PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE MEDICARE 5% NATIONAL SAMPLE DATA 2006-2007

 

Lokhandwala T, Yang Y, Thumula V, Bentley JP, Strum M, Banahan BF, Null K
University of Mississippi, University, MS, USA

PCV18

MEDICATION ADHERENCE AND HOSPITALIZATION AMONG CHRONIC HEART FAILURE MEDICARE BENEFICIARIES WITH AND WITHOUT DEPRESSION

 

Chhabra P, Dutcher SK, Rattinger GB, Zuckerman IH, Simoni-Wastila L, Gottleib SS, Stuart B
University of Maryland, Baltimore, Baltimore, MD, USA

PCV19

A BAYESIAN MULTIPLE TREATMENT COMPARISON OF PULMONARY ARTERIAL HYPERTENSION DRUG CLASSES BASED ON THE RISK OF MORTALITY REPORTED IN CLINICAL TRIALS

 

Mutebi A, Malone D
University of Arizona, Tucson, AZ, USA

PCV20

PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY

 

Chodick G, Shalev V, Goldstein I, Porath A, Simah V
Maccabi Healthcare Services, Tel Aviv, Israel

PCV21

EFFECTS OF AZILSARTAN MEDOXOMIL VERSUS VALSARTAN AND OLMESARTAN MEDOXOMIL ON THE ACHIEVEMENT OF SYSTOLIC BLOOD PRESSURE GOALS AMONG HYPERTENSIVE PATIENTS WITH DIABETES

 

Sussman M1, Leahy M2, Friedman M1, Menzin J1, Nichols C1, Neumann P3, Sullivan SD4
1Boston Health Economics, Inc., Waltham, MA, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 3Tufts University School of Medicine, Boston, MA, USA, 4University of Washington, Seattle, WA, USA

PCV22

META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE

 

Dranitsaris G1, Jelincic V1, Choe Y2
1Augmentium Pharma Consulting, Toronto, ON, Canada, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCV23

COMPARING THE EFFECTIVENESS OF ROSUVASTATIN AND ATORVASTATIN IN PREVENTING CARDIOVASCULAR OUTCOMES: ESTIMATES USING THE ARCHIMEDES MODEL

 

Schuetz CA1, van Herick A1, Alperin P1, Peskin B1, Hsia J2, Gandhi SK2
1Archimedes, Inc., San Francisco, CA, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV24

EVALUATION OF THE CLINICAL FACTORS AND PREVENTIVE MEDICATIONS ASSOCIATED WITH THE LENGTH OF HOSPITAL STAY AMONG ISCHEMIC STROKE PATIENTS

 

Al-Jabi SW1, Hassan Y1, Abd Aziz N1, Looi I2, Zyoud SH1
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2Pulau Pinang Hospital, Pinang, Malaysia

PCV25

MANAGEMENT OF ACUTE ISCHEMIC STROKE AND ITS LONG TERM EVOLUTION IN THE UNITED STATES AND CANADA

 

Rouleau A, Gobaux V, Guilhaume C, Yiou A, Milea D
Lundbeck SAS, Issy-les-Moulineaux, France

PCV26

EFFECTS OF THIAZOLIDINEDIONES ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION

 

Yeh SZ1, Hsieh CF2, Tsai YW3, Huang WF2
1AstraZeneca, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan, 3Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan

PCV27

IS ANEMIA ASSOCIATED WITH HEART FAILURE? NHANES DATABASE (2005-2006) ANALYSIS

 

Alsalman AJ, Alhammad AM, Alhashem YN, Al Hawaj MA, Van Tassell BW, Harpe SE
Virginia Commonwealth University, Richmond, VA, USA

PCV28

CARDIOVASCULAR RISK FACTORS AMONG CHINESE AND WHITE ADULTS IN THE UNITED STATES

 

McDonald M, Zhou J, Rubinstein E, Mardekian J
Pfizer, Inc., New York, NY, USA

PCV29

IMPROVING BLEEDING RISK ASSESSMENT FOR ANTICOAGULANT USE IN ATRIAL FIBRILLATION

 

Lee EH1, Kwong WJ1, Casciano J2, Martin B3
1Daiichi Sankyo, Inc., Parsippany, NJ, USA, 2eMAX Health Systems, LLC, White Plains, NY, USA, 3University of Arkansas for Medical Sciences, Little Rock, AZ, USA

PCV30

A META-ANALYSIS OF RISK FACTORS TO DEVELOP CARDIOVASCULAR EVENTS AND STROKE IN SUBJECTS EXPOSED TO ENVIROMENTAL TOBACCO SMOKE

 

Villasis-Keever M1, Rendón-Macias M1, Escamilla_Nuñez A1, Mould-Quevedo JF2, Muciño-Ortega E3, Galindo-Suarez RM3
1Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico, 2Pfizer, New York, NY, USA, 3Pfizer, Mexico City, Mexico

PCV31

ASSOCIATION BETWEEN HEART FAILURE AND IN-HOSPITAL MORTALITY IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

 

Phatak H1, Pan X2, Kawabata H1
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb, New Haven, CT, USA

Cardiovascular Disorders – Cost Studies

PCV32

BUDGET IMPACT ANALYSIS OF INCREASING LMWH/FXI UTILIZATION

 

Schilling B1, Powers A2, Faria C2, Choe Y2, Broder M3, Bentley T4
1Aspen MedAssets, Denver, CO, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 4PharLLC, Beverly Hills, CA, Albania

PCV33

USE OF SECONDARY DATA SOURCES TO ESTIMATE INPATIENT COSTS AND PAYMENTS FOR ACUTE CORONARY SYNDROME

 

Ohsfeldt R1, Bhandary D2, Fox KM3, Gandhi SK2
1Texas A&M Health Science Center, College Station, TX, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, USA

PCV34

PROPHYLAXIS USE AND 90-DAY COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENT ANALYSIS IN HOSPITALIZED MEDICALLY ILL PATIENTS

 

Baser O1, Xie L1, Yuce H2, Du J1, Wang L1
1STATinMED Research, Ann Arbor, MI, USA, 2New York City College of Technology-CUNY / STATinMED Research, New York, NY, USA

PCV35

COMPARISON OF MAJOR BLEEDING RELATED MORTALITY, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

 

Baser O, Du J, Xie L, Baser E
STATinMED Research, Ann Arbor, MI, USA

PCV36

EVALUATION OF THE HOSPITAL RESOURCE UTILIZATION ASSOCIATED WITH TOLVAPTAN USAGE AMONG HEART FAILURE PATIENTS WITH HYPONATREMIA FROM THE EVEREST TRIAL

 

Dasta JF1, Chiong JR2, Kim S3, Lin J4
1Ohio State University, Columbus, OH, USA, 2Loma Linda University, Loma Linda, CA, USA, 3Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA, 4Novosys Health, Flemington, NJ, USA

PCV37

WITHDRAWN

 

 

PCV38

POTENTIAL ECONOMIC IMPACT OF DYSPNEA ASSOCIATED WITH TICAGRELOR USE

 

Bonafede M1, Jing Y2, Gdovin Bergeson J2, Liffmann DK3, Makenbaeva D2, Graham JP2, Deitelzweig S4
1Thomson Reuters, Andover, MA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Thomson Reuters, Washington, DC, USA, 4Ochsner Health System, New Orleans, LA, USA

PCV39

CHARACTERIZATION OF COSTS ASSOCIATED WITH STROKE REHABILITATION: A REVIEW OF THE LITERATURE

 

Sacco P, Johnson J, Verma A
Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV40

COST AND PRACTICE OF TREATMENT OF ACUTE ISCHEMIC STROKE IN REAL WORLD SETTINGS IN RUSSIA

 

Vorobyev P, Bezmelnitsyna L, Borisenko O
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

PCV41

AN ESTIMATE OF SOCIETAL MONETARY BENEFITS OF SIMVASTATIN IN CANADA

 

Thanh NX, Chuck A, Ohinmaa A, Jacobs P
Institute of Health Economics, Edmonton, AB, Canada

PCV42

A DECISION MODELING APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION

 

Rao S, Lin FJ, Ojo O, Patel V, Yu S, Zhan L, Touchette DR
University of Illinois at Chicago, Chicago, IL, USA

PCV43

COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT

 

Vorobyev P1, Krasnova L2, Borisenko O1, Lukyantseva D2, Bashlakova E2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PCV44

CHANGING COST-EFFECTIVENESS EARLY IN THE PRODUCT LIFE CYCLE: THE EXAMPLE OF CLOPIDOGREL BISULFATE

 

van der Goes DN1, Willke RJ2, Garrison L3
1University of Washington, Seattle, WA, USA, 2Pfizer, Inc., New York, NY, USA, 3University of Washington Department of Pharmacy, Seattle, WA, USA

PCV45

COST-EFFECTIVENESS OF CYP2C9 AND VKORC1 GENOTYPE-GUIDED WARFARIN ANTICOAGULATION CARE: THE IMPLEMENTATION OF DISCRETE EVENT SIMULATION MODEL ON THE NATURAL HISTORY OF VENOUS THROMBOEMBOLISM

 

Teschemaker R1, Lawrence W2, Wutoh AK3
1Howard University, Washington, DC, USA, 2Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA, 3Howard University, Hyattsville, MD, USA

PCV46

LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY

 

Henriksson M1, Nikolic E2, Janzon M3, Hauch O4, Levin LÅ2, Wallentin L5
1AstraZeneca Nordic, Södertälje, Sweden, 2Linköping University, Linköping, Sweden, 3Linköping University, Linköping University Hospital, Linköping, Sweden, 4AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 5Uppsala University, Uppsala, Sweden

PCV47

COST-EFFECTIVENESS OF FONDAPARINUX AND ENOXAPARIN IN PATIENTS WITH NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN BRAZIL

 

Pepe C1, Machado M2, Olimpio A2, Canella M2, Ramos R3
1MedInsight Evidências, Campinas, SP, Brazil, 2GlaxoSmithKline Brazil, Rio de Janeiro, Brazil, 3Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil

PCV48

COST-EFFECTIVENESS ANALYSIS OF ANTIARRHYTHMIC THERAPIES FOR THE TREATMENT OF SUPRAVENTRICULAR TACHYCARDIA AND SURGICALLY INDUCED TACHYCARDIAS AND HYPERTENSION

 

Dexter F1, Yang J2, Carlton R3, Bramley T3, Harb G2
1University of Iowa, Iowa City, IA, USA, 2Baxter Healthcare Corporation, New Providence, NJ, USA, 3Xcenda, LLC., Palm Harbor, FL, USA

PCV49

COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

 

Vorobyev P1, Krasnova L2, Borisenko O1, Lukyantseva D2, Bashlakova E2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PCV50

COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

 

Zhao Y1, Lim L1, Coleman CI2
1Yale-Griffin Hospital, Derby, CT, USA, 2University of Connecticut School of Pharmacy, Storrs, CT, USA

PCV51

THE VALUE OF ATORVASTATIN OVER THE PRODUCT LIFE CYCLE

 

Grabner M1, Johnson WR2, Abdulhalim AM1, Kuznik A3, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA, 3Pfizer, Inc., New York City, NY, USA

PCV52

COST-EFFECTIVNESS STUDY OF CITICOLINE IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN RUSSIA

 

Vorobyev P, Bezmelnitsyna L, Borisenko O
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

PCV53

COST-EFFECTIVENESS ANALYSIS COMPARING IVABRADINE WITH ISOSORBIDE MONONITRATE, AMLODIPINE, DILTIAZEM AND VERAPAMIL, IN THE TREATMENT OF STABLE ANGINA PECTORIS

 

Ergene O1, Erol MK2, Oto A3, Kucukoglu S4, Ozdemir O5, Tan M6
1Izmir Ataturk Training and Research Hospital, Izmir, Turkey, 2Erzurum Ataturk University School of Medicine, Erzurum, Turkey, 3Hacettepe University School of Medicine, Ankara, Turkey, 4Istanbul University Institute of Cardiology, Istanbul, Turkey, 5Yorum Consulting Ltd., Istanbul, Turkey, 6Servier Ilac ve Arastirma A.S., Istanbul, Turkey

PCV54

EFFECTIVENESS OF DISEASE MANAGEMENT CARE IN THE CASE OF HEART FAILURE

 

Ugiliweneza B
University of Louisville, Louisville, KY, USA

PCV55

COST-MINIMIZATION ANALYSIS OF THROMBOPROPHYLAXIS FOLLOWING ELECTIVE TOTAL HIP ARTHROPLASTY

 

Delate T, Clark N, Cho S, Witt D
Kaiser Permanente Colorado, Aurora, CO, USA

PCV56

COST-MINIMIZATION ANALYSIS OF LANDIOLOL FOR CT SCANNING FOR CVD SUSPICIOUS PATIENTS IN JAPAN

 

Igarashi A1, Fujito K2, Fukuda T3
1Tokyo University Faculty of Pharmacy, Tokyo, Japan, 2Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, 3Tokyo University, Tokyo, Japan

PCV57

HEALTH CARE RESOURCE UTILIZATION AMONG T2DM PATIENTS WITH PRE-EXISTING MACROVASCULAR CONDITIONS: A MATCHED COHORT STUDY

 

Qiu Y1, Fu AZ2
1Merck & Co., Inc., Whitehouse Station, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA

PCV58

ASSOCIATION BETWEEN HEART FAILURE AND RESOURCE UTILIZATION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

 

Pan X1, Kawabata H2, Phatak H2
1Bristol-Myers Squibb, New Haven, CT, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

Cardiovascular Disorders – Patient-Reported Outcomes & Preference-Based Studies

PCV59

PERSISTENCE AND COMPLIANCE IN HYPERTENSIVE PATIENTS TREATED WITH FIXED OR UNFIXED COMBINATIONS OF ANGIOTENSIN RECEPTOR BLOCKERS, AMPLODIPINE AND HYDROCHLOROTHIAZIDE

 

Sandberg A1, Kostev K2, Ehlken B3, Holz B2, Oberdiek A1
1Daiichi Sankyo Europe GmbH, Munich, Germany, 2IMS Health GmbH & Co., Frankfurt, Germany, 3IMS Health GmbH & Co., Munich, Germany

PCV60

MEDICATION ADHERENCE, PERSISTENCE, AND HEALTH CARE COSTS FOR PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

 

Zhao Z1, Peng X1, Bae JP1, Dungey J1, Faries DE1, Sponseller CA2, Wetmore S1, Yu CY1, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA

PCV61

THE IMPACT OF THE MEDICARE DOUGHNUT HOLE ON MEDICATION USE BEHAVIORS AND HEALTH CARE RESOURCE UTILIZATION AMONG BENEFICIARIES TAKING STATIN MEDICATION

 

Joshi N, Banahan BFI, Pace PF
University of Mississippi, University, MS, USA

PCV62

PERSISTENCE AND COMPLIANCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL – ANALYSIS OF REAL-LIFE PRESCRIPTION DATA

 

Sandberg A1, Kostev K2, Ehlken B3, Holz B2, Oberdiek A1
1Daiichi Sankyo Europe GmbH, Munich, Germany, 2IMS Health GmbH & Co., Frankfurt, Germany, 3IMS Health GmbH & Co., Munich, Germany

PCV63

THE IMPACT OF CARDIOVASCULAR DISEASE HOSPITALIZATIONS ON CHANGES IN PATIENT ADHERENCE TO ANTIHYPERTENISVE DRUGS IN A MEDICAID POPULATION

 

Yan X, Shaya FT
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCV64

ADHERENCE TO MEDICATIONS WITH ONCE-A-DAY (QD) AND TWICE-A-DAY (BID) DOSING FORMULATIONS IN ACUTE CORONARY SYNDROME (ACS) PATIENTS

 

Hess G1, Bhandary D2, Fonseca E3, Kumar D3, Potter D2, Smith D2, Gandhi SK2
1SDI, Leonard Davis Institute, University of Penn, Plymouth Meeting, PA, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3SDI, Plymouth Meeting, PA, USA

PCV65

NEW STATIN USERS' PERSISTENCE AND ADHERENCE: BOTH ARE CRITICAL CONCEPTS IN THE COMPREHENSIVE CHARACTERIZATION OF MEDICATION EXPOSURE

 

Slejko JF1, Valuck RJ1, Ho PM2, Anderson HD1, Nair KV1, Campbell JD1
1University of Colorado School of Pharmacy, Aurora, CO, USA, 2University of Colorado, Denver School of Medicine and U.S. Department of Veterans Affairs, Denver, CO, USA

PCV66

ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC VERSUS BRAND STATIN THERAPY

 

Chen Q1, Kachur SG2, Fatodu H2, Garber H2
1Johns Hopkins Bloomsberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins HealthCare, Glen Burnie, MD, USA

PCV67

EXAMINING MEDICATION ADHERENCE AMONG TRICARE BENEFICIARIES RECEIVING STATIN THERAPY FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MILITARY TREATMENT FACILITIES IN THE UNITED STATES

 

Nwokeji E1, Yarger S1, Trice S2, Chao S3, Devine J2, Potyk R2, Gutke G3, Bonnema A3
1Department of Defense/GDIT, Fort Sam Houston, TX, USA, 2Department of Defense, Fort Sam Houston, TX, USA, 3Air Force Medical Support Agency, San Antonio, TX, USA

PCV68

FACTORS ASSOCIATED WITH NON-ADMINISTRATION OF ORDERED PHARMACOLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS DOSES

 

Shermock KM1, Shafir V2, Streiff MB3, Lavallee DM4, Pinto BL1, Haut E3, Kraus P5, Efird L5, Elder S5, Rand C3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2Philadelphia College of Pharmacy, Philadelphia, PA, USA, 3The Johns Hopkins University School of Medicine, Baltimore, MD, USA, 4Center for Medical Technology and Policy, Baltimore, MD, USA, 5The Johns Hopkins Hospital, Baltimore, MD, USA

PCV69

IMPACT OF COMMUNITY PHARMACIST-LED COUNSELING ON IMPROVING MEDICATION ADHRERENCE

 

Jiang JZ, Khandelwal N, Rudkin K, Duncan I
Walgreens, Deerfield, IL, USA

PCV70

VARIATIONS IN THE IMPACT OF ILLNESS PERCEPTIONS AND MEDICATION BELIEFS ON MEDICATION COMPLIANCE OF ELDERLY VERSUS GERIATRIC HYPERTENSIVE COHORTS: A COMPARATIVE ANALYSIS

 

Rajpura JR1, Nayak R2
1Purdue University, West Lafayette, IN, USA, 2St. John's University, Jamaica, NY, USA

PCV71

EVALUATING MEDICATION ADHERENCE WITH CHRONIC CARDIOVASCULAR THERAPIES AMONG UNINSURED WORKING ADULTS: RESULTS FROM THE TEXAS DEMONSTRATION TO MAINTAIN INDEPENDENCE AND EMPLOYMENT (DMIE) STUDY

 

Nwokeji E1, Bohman T1, Reed B2, Wallisch L1, Ostermeyer B2, Stoner D3, Spence R1
1University of Texas at Austin, Austin, TX, USA, 2Baylor College of Medicine, Houston, TX, USA, 3Texas Department of State Health Services, Austin, TX, USA

PCV72

THE RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS DIAGNOSED WITH ATRIAL FIBRILLATION IN THE UNITED STATES

 

Gupta S1, Wagner JS2, Goren A2, DiBonaventura M2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

PCV73

CONSTRUCT VALIDITY OF HEALTH UTILITIES INDEX (HUI) JAPANESE VERSION: CROSS-SECTIONAL STUDY FOR STROKE IN JAPAN

 

Noto S1, Uemura T2, Izumi R1, Moriwaki K1
1Niigata University of Health and Welfare, Niigata, Japan, 2Kyorin University, Tokyo, Japan

PCV74

ASSESSMENT OF KNOWLEDGE ABOUT HYPERTENSION (HTN) AMONG HYPERTENSIVE PATIENTS IN SOUTHERN PUNJAB, PAKISTAN

 

Atif M1, Asif M2, Saleem F1, Ahmad N1, Saqib N3
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan, 3Ministry of Health, Karachi, Sindh, Pakistan

PCV75

EFFECT OF ACEI AND ARB ON HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION AND DIABETES

 

Johnson ML, Parikh R, Rajan SS, Aparasu R
University of Houston, Houston, TX, USA

PCV76

PATIENT SYMPTOM EXPERIENCES FOLLOWING A MYOCARDIAL INFARCTION

 

Gwaltney C1, Martin ML2, Falvey H3
1Brown University, Providence, RI, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Novartis Pharma AG, Basel, Switzerland

PCV77

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION IN KOREA

 

Jeong MH1, Kim DS2, Chang HJ3, Hong GR4, Park SW5, Ko SK6, Park HJ6
1Chonnam National University Hospital, Gwangju, South Korea, 2Inje University Pusan Paik Hospital, Busan, South Korea, 3Sevrance Hospital, Yonsei University, Seoul, South Korea, 4Yeungnam University Medical Center, Daegu, South Korea, 5Samsung Medical Center, Seoul, South Korea, 6Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea

PCV78

HEALTH RELATED QUALITY OF LIFE IN HYPERTENSIVE PATIENTS VISITING PUBLIC HOSPITALS OF QUETTA, PAKISTAN

 

Saleem F1, Hassali MA1, Shafie AA1, Bashir S2
1Universiti Sains Malaysia (USM), Pinang, Malaysia, 2University of Sargodha, Sargodha, Punjab, Pakistan

Cardiovascular Disorders – Health Care Use & Policy Studies

PCV79

IMPACT OF DISEASE MANAGEMENT PROGRAM "DE TODO CORAZON" OF MUTUAL SER HMO TO CONTROL CARDIOVASCULAR RISK, COHORT 2004-2009, COLOMBIA

 

Paz JJ1, Granados CE2, Morales C1, Rodriguez N2, Buitrago LA2, Guete A3, Caceres HA4, Ramirez P4, Pardo R2
1Mutual ser EPSS, Cartagena, Colombia, 2Universidad Nacional de Colombia, Bogotá, Colombia, 3Pfizer S.A., Cartagena, Colombia, 4Pfizer S.A., Bogotá, Colombia

PCV80

MEDICATION THERAPY MANAGEMENT IMPROVES HEALTH CARE UTILIZATION AND COSTS FOR EMPLOYERS

 

Pinto SL, Partha G, Jania A
University of Toledo, Toledo, OH, USA

PCV81

SUSTAINING CLINICAL OUTCOMES OVER 24 MONTHS: IS MEDICATION THERAPY MANAGEMENT (MTM) THE ANSWER?

 

Pinto SL1, Jania AW1, Coehrs B2, Riepenhoff C2
1University of Toledo, Toledo, OH, USA, 2The Pharmacy Counter, LLC, Toledo, OH, USA

PCV82

EVALUATION OF RELATIONSHIP BETWEEN BLOOD PRESSURE CONTROL AMONG HYPERTENSIVE PATIENTS AND INTEGRATION OF SERVICES WITHIN PHYSICIAN ORGANIZATIONS

 

Smalarz A1, Fraser K1, Wong K2, Wu N1, Wogen J3, Boulanger L1
1United BioSource Corporation, Lexington, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3MedMentis Consulting, LLC, Towaco, NJ, USA

PCV83

GAPS AND UNMET NEEDS IN ANTIPLATELET THERAPIES FOR ACUTE CORONARY SYNDROME (ACS) AND CHRONIC CORONARY HEART DISEASE (CHD)

 

Lian J1, Azmi S2, Navaratnam P3
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Azmi Burhani Consulting Sdn Bhd, Petaling Jaya, Selangor, Malaysia, 3DataMed Solutions LLC, Hilliard, OH, USA

PCV84

EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE

 

Martinez Valverde S1, Reyes Morales H2, Castro Rios A3, Perez Cuevas R3, Klunder Klunder M1, Salinas Escudero G1
1Hospital Infantil de México Federico Gómez, Mexico City, D.F., Mexico, 2Instituto Nacional de Salud Pública, Morelos, Mexico, 3Mexican Institute for Social Security (IMSS), Mexico City, D.F., Mexico

PCV85

TREATMENT FOR DEPRESSION IN WOMEN WITH HYPERTENSION

 

Atkins E, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PCV86

INSURANCE STATUS AND THE USE OF ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) AND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS AMONG POST-MYOCARDIAL INFARCTION (MI) PATIENTS

 

Kaisaeng N, Zhang J
Virginia Commonwealth University, Richmond, VA, USA

PCV87

FACTORS ASSOCIATED WITH SELECTIONS OF STATINS AMONG ELDERLY PATIENTS

 

Zhao Z1, Peng X1, Bae JP1, Sponseller CA2, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA

PCV88

PATTERNS OF STATIN PRESCRIPTION AMONG PRIVATELY INSURED COMMERCIAL AND MEDICARE PATIENTS

 

Bae JP1, Peng X1, Zhao Z1, Zagar A1, Sponseller CA2, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA

PCV89

COMPARISON OF DOSING PATTERNS AMONG PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

 

Zhao Z1, Peng X1, Bae JP1, Dungey J1, Faries DE1, Sponseller CA2, Wetmore S1, Yu CY1, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA

PCV90

FACTORS ASSOCIATED WITH SELECTIONS OF STATINS AMONG PATIENTS IN A LARGE EMPLOYER-BASED CLAIMS DATABASE

 

Zhao Z1, Peng X1, Bae JP1, Sponseller CA2, LeNarz LA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kowa Pharmaceuticals America, Inc., Montgomery, AL, USA

PCV91

BETA BLOCKERS AND DIURETICS USAGE IN CROATIA AND SLOVENIA DURING A NINE-YEAR PERIOD

 

Vitezic D1, Kucan M2, Vitezic M3, Kovacevic M1, Mrsic Pelcic J4
1University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, 2JADRAN Galenski laboratorij, Rijeka, Croatia, 3University of Rijeka Medical School and Orthopedic Hospital Lovran, Lovran, Croatia, 4University of Rijeka, Rijeka, Croatia

PCV92

CHANGES IN THE PREVALENCE, TREATMENT AND CONTROL OF HYPERTENSION IN GERMANY? A CLINICAL-EPIDEMIOLOGICAL EXAMINATION OF 50,000 PRIMARY CARE PATIENTS WITH THE DETECT STUDY

 

Labeit A1, Klotsche J2, Pieper L2, Wehling M3, Wittchen HU2
1University of Leicester, Leicester, UK, 2Technische Universität Dresden, Dresden, Germany, 3Universität Heidelberg - Medizinische Fakultät Mannheim, Mannheim, Germany

PCV93

HEALTH EXPENDITURE COMPARISON OF METOPROLOL SUCCINATE VS METOPROLOL TARTARATE

 

Vaidya V, Patel P
University of Toledo, Toledo, OH, USA

PCV94

ANTICOAGULANT USE, THE PREVALENCE OF BRIDGING AND RELATION TO LENGTH OF STAY AMONG HOSPITALIZED PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

 

Smoyer-Tomic K1, Sander S2, Siu K2, Smith DM3, Amin A4, Johnson BH1
1Thomson Reuters, Washington, DC, USA, 2Boehringer Ingelheim, Ridgefield, CT, USA, 3Thomson Reuters, Montvale, NJ, USA, 4University of California, Irvine, Irvine, CA, USA

PCV95

USING COMPUTERIZED PHYSICIAN ORDER ENTRY OF ANTI-HYPERTENSIVE MEDICATIONS TO CONNECT INDICATIONS WITH PRESCRIBING AND IMPROVE PROBLEM LIST DOCUMENTATION

 

Galanter W, Walton S, Falck S, Rosencranz H, Adimadhyam S
University of Illinois Chicago, Chicago, IL, USA

PCV96

TREND IN THE UTILIZATION OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT STRATEGIES IN THE MANAGEMENT OF NEWLY DIAGNOSED ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES

 

Kashyap A, Li C
University of Arkansas for Medical Sciences, Little Rock, AR, USA

PCV97

IS CARDIOVASCULAR MEDICATION USAGE A MARKER FOR CARDIOVASCULAR RISK? POTENTIAL IMPLICATION FOR SMART-EDIT FORMULARY MANAGEMENT STRATEGIES

 

Hunter TD1, Gunnarsson C1, Bullano MF2, de Vane PJ2
1S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV98

USE OF ELECTRONIC MEDICAL RECORDS TO ASSESS THE CLINICAL AND ECONOMIC IMPACT OF NON-MEDICAL SWITCHING BETWEEN DIFFERENT ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)

 

Kamal KM1, Zacker C2, Civitarese L3
1Duquesne University, Pittsburgh, PA, USA, 2Novartis Pharmaceuticals, Emmaus, PA, USA, 3Preferred Primary Care Physicians, Carnegie, PA, USA

PCV99

MEDICAL RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITALIZATION OF PATIENTS WITH CHRONIC HEART FAILURE IN THE UNITED STATES

 

Korves C1, Eldar-Lissai A1, Rodermund D1, Swallow E1, Cummings AK1, Ariely R2, Duh MS1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCV100

HEALTH CARE UTILIZATION AND COSTS FOR A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

 

Pinto SL, Partha G
University of Toledo, Toledo, OH, USA

PCV101

EXPLORING GENDER DISPARITIES IN PREVENTIVE CARE UTILIZATION AMONGST UNITED STATES POPULATION

 

Vaidya V, Partha G, Karmakar M
University of Toledo, Toledo, OH, USA

PCV102

COMPLICATIONS ARISING DURING HOSPITALIZATION FOR HEMORRHAGIC OR ISCHEMIC STROKE: EVIDENCE FROM A LARGE ADMINISTRATIVE DATABASE

 

Candrilli SD, Karve SJ, Wirth PE
RTI Health Solutions, Research Triangle Park, NC, USA

PCV103

PHARMACIST INTERVENTIONS WITHIN A COMMUNITY PHYSICIAN BASED MEDICAL HOME PRACTICE: DIABETES CLINICAL OUTCOMES

 

Willey VJ1, Reinhold JA1, Kozuch JM1, Amin SM1, Kelly BL2, Kim EA2, Willey KH2
1University of the Sciences, Philadelphia, PA, USA, 2Quality Family Physicians, Hockessin, DE, USA

PCV104

REAL-WORLD SIDE EFFECT DATA ON CHOLESTEROL MEDICATIONS – OUTPUTS FROM AN ONLINE PATIENT COMMUNITY

 

Cascade E1, Plummer RC2, Mangini NS2
1MediGuard.org, Rockville, MD, USA, 2MediGuard.org, Princeton, NJ, USA

PCV105

THE INITIATION AND EXTENT OF DOSE TITRATION OF ACE INHIBITORS AND Β-BLOCKERS POST ACUTE MYOCARDIAL INFARCTION: A PROSPECTIVE AUDIT

 

Alowayesh MS1, Wright P2
1Virginia Commonwealth University, Richmond, VA, USA, 2The London Chest Hospital, London, UK

PCV106

RE-HOSPITALIZATION RATES OF ACUTE CORONARY SYNDROME PATIENTS IN REAL WORLD CLINICAL PRACTICE: OBSERVATIONS FROM A NATIONAL ADMINISTRATIVE CLAIMS DATA

 

Tunceli O1, Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, Singer J1
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PCV107

IDENTIFYING EFFICIENT ACUTE CLINICAL PATHWAYS FOR CHEST PAIN: USING RISK ADJUSTED COST-EFFECTIVENESS (RAC-E) TO COMPARE HOSPITALS USING LINKED, ROUTINELY COLLECTED DATA

 

Caffrey O1, Pham C2, Karnon J2, Ben-Tovim DI3, Hakendorf P3, Crotty M4
1University of Birmingham, Birmingham, Warwickshire, UK, 2University of Adelaide, Adelaide, South Australia, Australia, 3Flinders Medical Centre, Adelaide, South Australia, Australia, 4Flinders University, Adelaide, South Australia, Australia

PCV108

CARDIOVERSION TREATMENT PATTERNS AND OUTCOMES AMONG ACUTE ATRIAL FIBRILLATION PATIENTS IN 5 EUROPEAN COUNTRIES

 

Buono JL1, Russell T2, Worsfold A2, Bash LD3
1St. John's University, Queens, NY, USA, 2Adelphi Real World, Macclesfield, UK, 3Merck & Co., Inc., Whitehouse Station, NJ, USA

Cardiovascular Disorders – Research on Methods

PCV109

BEYOND CASE FATALITY: A NEW METHOD TO ESTIMATE THE EFFECT OF INCREASING TREATMENT UPTAKE ON MORTALITY

 

Mitsakakis N1, Wijeysundera HC2, Krahn M1
1Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada

PCV110

DEVELOPMENT AND VALIDATION OF A SHORT PRO MEASURE OF HEALTH STATUS FOR INDIVIDUALS WITH ACUTE MYOCARDIAL INFARCTION: THE MYOCARDIAL INFARCTION DIMENSIONAL ASSESSMENT SCALE (MIDAS)

 

Jenkinson C1, Thompson D2, Roebuck A3, Churchman D4
1University of Oxford, Health Services Research Unit, Oxford, Oxfordshire, UK, 2Australian Catholic University, Melbourne, Victoria, Australia, 3United Lincolnshire NHS Trust, Lincoln, Lincolnshire, UK, 4Isis Innovation Ltd., Oxford, Oxfordshire, UK

PCV111

IDENTIFICATION OF RESPONSE SHIFT AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE USING TWO STRUCTURAL EQUATION MODELING TECHNIQUES

 

Gandhi PK1, Ried LD2, Huang IC1, Kimberlin C1, Kauf T1, Suh DC3
1University of Florida, Gainesville, FL, USA, 2Southwestern Oklahoma State University, Weatherford, OK, USA, 3School of Pharmacy, Rutgers University, Piscataway, NJ, USA

PCV112

EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT

 

Na Y, Lee EK
Sookmyung Women's University, Seoul, South Korea

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 23, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 23, 2011 - 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 23, 2011 - 6:30PM – 7:30PM
DISMANTLE: Monday, May 23, 2011 - 8:30PM – 9:00PM

Sensory Systems Disorders – Clinical Outcomes Studies

PSS1

STEVENS-JOHNSON AND RED MAN SYNDROME: A CASE REPORT ON ADVERSE DRUG REACTIONS OF SIMULTANEOUS USE OF PHENYTOIN AND VANCOMYCIN

 

Kler SK
Department of General Medicine, Government Medical College & Hospital, Chandigarh, India

PSS2

DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES

 

Schaumberg DA1, Li JZ2
1Brigham and Women's Hospital, Boston, MA, USA, 2Pfizer, Inc., San Diego, CA, USA

PSS3

PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL

 

Chodick G, Shalev V, Goldstein I, Sror M
Maccabi Healthcare Services, Tel Aviv, Israel

PSS4

SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

 

Berbari J1, Reynolds S1, Heil-Ruess M2, Iskedjian M3
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2MHR - Nutrition Marketing Services, Lausanne, Switzerland, 3PharmIdeas Research and Consulting, Oakville, ON, Canada

PSS5

WHAT INFLUENCES DENTAL CARE AMONG CHILDREN?

 

Hufstader M1, Vaidya V2, White-Means S3, Dishmon B4, Sudharshan L1, Sharma G1
1Covance Market Access Services, Gaithersburg, MD, USA, 2University of Toledo, Toledo, OH, USA, 3University of Tennessee, Memphis, TN, USA, 4Paradigm Dental, Memphis, TN, USA

PSS6

SAFETY PROFILE OF LATANOPROST VERSUS TIMOLOL IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION: POST 2000 SETTING

 

Gupta J, Siddiqui MK, Jindal R, Sehgal M
Heron Health Private Ltd, Chandigarh, Chandigarh, India

Sensory Systems Disorders – Cost Studies

PSS7

MEDICAL CARE COSTS ASSOCIATED WITH VISION LOSS IN TAIWAN

 

Wang MT1, Ng K2, Lo YW1, Lee WJ1, Wu BJ1, Yeh WS3
1National Defense Medical Center, Taipei, Taiwan, 2Allergan Singapore Pte Ltd, Singapore, 3Allergan, Irvine, CA, USA

PSS8

SYSTEMATIC REVIEW OF THE ECONOMIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

 

Iskedjian M1, Navarro V2, Khondoker F1, Farah B3
1PharmIdeas Research and Consulting, Oakville, ON, Canada, 2PharmIdeas Europe SAS, Lyon, France, 3PharmIdeas Research and Consulting, Ottawa, ON, Canada

PSS9

COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING

 

Waycaster C
Healthpoint Ltd., Fort Worth, TX, USA

PSS10

A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO

 

Vargas-Valencia J1, Sotelo-Guzmán M1, Mould-Quevedo JF2, Muciño-Ortega E3, Galindo-Suarez RM3
1Econopharma Consulting S. A. de C. V., Mexico City, Mexico, 2Pfizer, New York, NY, USA, 3Pfizer, Mexico City, Mexico

PSS11

COST-EFFECTIVENESS ANALYSIS OF FORMULARY MANAGEMENT STRATEGIES FOR FIRST-LINE AGENTS USED IN OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION

 

Blaser DA1, Ousterhout MM1, Gagnon JM1, Calabrese D2
1UMass Medical School, Shrewsbury, MA, USA, 2Med Metrics Health Partners, Worcester, MA, USA

PSS12

A DISCRETE EVENT SIMULATION TO OPTIMISE THE ALLOCATION OF CONSTRAINED HOSPITAL RESOURCES FOR GLAUCOMA

 

Crane GJ1, Karnon J1, Kymes S2, Casson R1, Metcalfe A1, Hiller JE1
1University of Adelaide, Adelaide, South Australia, Australia, 2Washington University, St. Louis, MO, USA

PSS13

INCREMENTAL COST-UTILITY ANALYSIS OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION

 

Kowalski J1, Yeh WS1, O'Leary B2, Ackerman S3, Sharma S4, Adena M5
1Allergan, Irvine, CA, USA, 2Covance Pty Ltd, North Ryde, NSW, Australia, 3Covance Market Access Services, Inc., San Diego, CA, USA, 4Queen's University, Kingston, ON, Canada, 5Datalytics Pty Ltd, Bruce, ACT, Australia

PSS14

COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM

 

Moeremans K1, Gerlier L1, Drieskens S2, Annemans L3, Brié H4, Deruyck M4, Faes P4, Vancayzeele S4
1IMS Health Consulting, Vilvoorde, Belgium, 2Panacea Officinalis BVBA, Brussels, Belgium, 3Ghent University - Brussels University, Ghent, Belgium, 4Novartis Pharma AG, Vilvoorde, Belgium

Sensory Systems Disorders – Patient-Reported Outcomes & Preference-Based Studies

PSS15

DEVELOPMENT OF A MULTIATTRIBUTE INSTRUMENT FOR ESTIMATING UTILITIES (PREFERENCE WEIGHTS) IN PEOPLE WITH GLAUCOMA FROM THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE (NEI-VFQ)

 

Kymes S1, Peters CM1, Beusterien K2, Kotak S3, Grinspan J2, Stwalley D4, Pleil A5
1Washington University School of Medicine, St. Louis, MO, USA, 2Oxford Outcomes Ltd., Bethesda, MD, USA, 3Pfizer, Inc., New York, NY, USA, 4Washington University, St. Louis, MO, USA, 5Pfizer, Inc., San Diego, CA, USA

PSS16

DEVELOPMENT OF A DISEASE SPECIFIC VERSION OF THE EQ-5D FOR USE IN PSORIASIS

 

Lloyd A1, Swinburn P1, Boye KS2, Edson E2, Bowman L2
1Oxford Outcomes Ltd., Oxford, Oxfordshire, UK, 2Eli Lilly and Company, Indianapolis, IN, USA

PSS17

THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

 

Mamolo CM1, Bushmakin AG2, Cappelleri JC2, Stewart M2
1Pfizer, Inc., New London, CT, USA, 2Pfizer Global Research and Development, Groton, CT, USA

PSS18

DISEASE SEVERITY EVALUATION AMONG DERMATOLOGICAL OUT-PATIENTS: A COMPARISON BETWEEN THE ASSESSMENTS OF PATIENTS AND PHYSICIANS

 

Tabolli S, Sampogna F, Pagliarello C, Paradisi A, Spagnoli A, Abeni D
IDI IRCCS, Rome, Italy

PSS19

PSYCHOMETRIC EVALUATION OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE 25 AND VISUAL FUNCTION QUESTIONNAIRE UTILITY INDEX IN PATIENTS WITH NON-INFECTIOUS INTERMEDIATE AND POSTERIOR UVEITIS

 

Naik RK1, Gries KS2, Rentz A3, Kowalski JW1, Revicki DA3
1Allergan, Inc., Irvine, CA, USA, 2United BioSource Corporation, Seattle, WA, USA, 3United BioSource Corporation, Bethesda, MD, USA

PSS20

MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS

 

Mamolo C1, Bushmakin AG2, Cappelleri JC2, Stewart M2
1Pfizer, New London, CT, USA, 2Pfizer Global Research and Development, Groton, CT, USA

PSS21

GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA

 

Dennee-Sommers B1, Galipeau N1, Fitzgerald K1, Evans C1, Daniels S2, Burgess SM2
1MAPI Values, Boston, MA, USA, 2Allergan, Inc., Irvine, CA, USA

PSS22

SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN WITH ATOPIC DERMATITIS

 

Iskedjian M1, Navarro V2, Khondoker F1, Farah B3
1PharmIdeas Research and Consulting, Oakville, ON, Canada, 2PharmIdeas Europe SAS, Lyon, France, 3PharmIdeas Research and Consulting, Ottawa, ON, Canada

Sensory Systems Disorders – Health Care Use & Policy Studies

PSS23

COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS

 

Naim A1, Pitts J2, Chen CY3, Wright D3, Chalk MB2, Edington D3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Chalk & Associates, Austin, TX, USA, 3University of Michigan, Ann Arbor, MI, USA

PSS24

MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE UNITED STATES

 

Patel P1, Lin HC2, Feldman SR3, Fleischer AB3, Nahata M4, Balkrishnan R2
1University of Georgia, Athens, GA, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Wake Forest University, Winston-Salem, NC, USA, 4Ohio State University, Columbus, OH, USA

PSS25

MEDICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS

 

Ou HT1, Feldman SR2, Balkrishnan R3
1University of Michigan College of Pharmacy, Ann Arbor, MI, USA, 2Wake Forest University, Winston-Salem, NC, USA, 3University of Michigan, Ann Arbor, MI, USA

PSS26

PATIENT'S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL INFLAMMATION TREATMENTS

 

Mattout P1, Rahhali N2, Watt M3, Auges M2, Taieb C2
1GEPI, Marseille, France, 2PFSA, Boulogne Billancourt, France, 3PFOC, Castres, France

Sensory Systems Disorders – Research on Methods

PSS27

EFFECT OF TREATMENT SWITCH ON THE COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN PERU AND COLOMBIA

 

Alandete JC
Janssen-Cilag, Bogota, Colombia

PSS28

EFFECT OF DIFFERENT RECALL PERIODS ON DRY EYE SYMPTOM RATINGS

 

Ruiz WM1, Li JZ2, Johnson ME3
1G&S Research, Inc., Indianapolis, IN, USA, 2Pfizer, Inc., San Diego, CA, USA, 3Bristol Eye Hospital, Bristol, UK

PSS29

DEVELOPMENT OF THE MODIFIED OCULAR COMFORT INDEX (MOCI)

 

Johnson ME1, Ruiz WM2, Li JZ3
1Bristol Eye Hospital, Bristol, UK, 2G&S Research, Inc., Indianapolis, IN, USA, 3Pfizer, Inc., San Diego, CA, USA

PSS30

BURDEN OF INFANTILE HEMANGIOMA: DEVELOPMENT OF A QUESTIONNAIRE

 

Taieb C1, Voisard JJ2, Ruiz F3
1PFSA, Boulogne Billancourt, France, 2PFD, Lavaur, France, 3Clinsearch, Bagneux, France

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 23, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 23, 2011 - 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 23, 2011 - 6:30PM – 7:30PM
DISMANTLE: Monday, May 23, 2011 - 8:30PM – 9:00PM

Systemic Disorders/Conditions – Clinical Outcomes Studies

PSY1

SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

 

Huang WF1, Hsiao FY2, Chou HC3, Tsai YW4, Yen HC5, Ke WM5
1National Yang-Ming University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan, 3Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 4Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 5Taiwan Drug Relief Foundation, Taipei, Taiwan

PSY2

THE ASSOCIATION BETWEEN THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND HEMOGLOBIN LEVEL

 

Chodick G1, Raz R1, Leshem E2, Steinvil A2, Berliner S2, Zeltser D3, Rogowski O2, Shalev V1
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

PSY3

OPIOIDS IN NON-MALIGNANT PAIN: ARE THEY EQUIVALENT IN SAFETY PROFILE? A NETWORK META-ANALYSIS

 

Siddiqui MK, Gupta J, Bhutani M, Sehgal M
Heron Health Private Ltd, Chandigarh, India

PSY4

TRENDS IN HYPONATREMIA MANAGEMENT AND ASSOCIATED OUTCOMES IN HOSPITAL SETTINGS: INTERIM RESULTS FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL REGISTRY IN HOSPITALIZED PATIENTS

 

Dasta JF1, Amin A2, Chiong JR3, Greenberg A4, Hauptman PJ5, Verbalis JG6
1Ohio State University, Columbus, OH, USA, 2University of California, Irvine, Irvine, CA, USA, 3Loma Linda University, Loma Linda, CA, USA, 4Duke University, Durham, NC, USA, 5Saint Louis University School of Medicine, Saint Louis, MO, USA, 6Georgetown University, Washington, DC, USA

PSY5

AN INVESTIGATION INTO THE RELATIONSHIP BETWEEN OBESITY AND SKIN AND SOFT TISSUE INFECTIONS REQUIRING HOSPITALIZATION

 

Swiney J
University of Kentucky, Lexington, KY, USA

PSY6

TRANSFUSIONAL IRON OVERLOAD (TIO) MONITORING AND TREATMENT: FINDINGS FROM AN ELECTRONIC MEDICAL RECORDS REVIEW STUDY AT THE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE

 

Duh MS1, Wetzstein G2, Guo A3, Sasane M3, Sarda SP1, Korves C1, Wang ST1, Wei R1, Clinton B1, Ray L2
1Analysis Group, Inc., Boston, MA, USA, 2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PSY7

A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE DISORDER ACQUIRED HEMOPHILIA: THE ACQUIRED HEMOPHILIA SURVEILLANCE (AHS) PROJECT

 

Lentz S1, Tandra A2, Doucette K3, Cooper DL3
1University of Iowa, Iowa City, IA, USA, 2Indiana Hemophilia & Thrombosis, Indianapolis, IN, USA, 3Novo Nordisk, Inc., Princeton, NJ, USA

Systemic Disorders/Conditions – Cost Studies

PSY8

DIRECT AND INDIRECT COSTS OF PRIVATELY-INSURED PATIENTS TREATED WITH OXYMORPHONE EXTENDED-RELEASE OR OXYCODONE CONTROLLED-RELEASE TABLETS

 

Kirson NY1, White A1, Birnbaum HG1, Schiller M2, Waldman T1, Ben-Joseph R3, Summers K3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Endo Pharmaceuticals, Chadds Ford, PA, USA

PSY9

HEALTH CONSEQUENCES AND COSTS OF TACHOSIL® AS HAEMOSTATIC TREATMENT IN LIVER SURGERY VERSUS TISSUCOL®: A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

 

Ortega A, Pardo F
Clínica Universitaria de Navarra, Pamplona, Spain

PSY10

COST ANALYSIS OF ANEMIA TREATMENT WITH ERYTHROPOIESES-STIMULATING AGENTS (ESAS) IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A MULTICOUNTRY APPROACH

 

Duran A1, Spaepen E2, Lamotte M3, Walter E4, Lucioni C5, Pinheiro B6, Brosa M7, Kutikova L8, Pujol B8, Annemans L9
1IMS Health, London, UK, 2SBD Analytics BVBA/SPRL, Bekkevoort, Belgium, 3IMS Health, Vilvoorde, Belgium, 4Institute for Pharmacoeconomic Research, Vienna, Austria, 5Wolters Kluwer Health Italy, Milan, Italy, 6Centro de Investigação Sobre Economia Portuguesa, Lisbon, Portugal, 7Oblikue Consulting, Barcelona, Spain, 8Amgen (Europe) GmbH, Zug, Switzerland, 9I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium

PSY11

BURDEN OF ILLNESS IN FIBROMYALGIA SYNDROME: THE PATIENTS' PERSPECTIVES

 

Lee SS1, Kim SH2, Kim SK3, Lee CK4, Lee HS5, Lee SH6, Park YB7, Ko SK8, Park HJ8
1Chonnam National University Hospital, Gwangju, South Korea, 2Inje University Haeundae Park Hospital, Busan, South Korea, 3Daegu Catholic University Medical Center, Daegu, South Korea, 4Asian Medical Center, Seoul, South Korea, 5Hanyang University Guri Hospital, Gyeonggi-do, South Korea, 6Konkuk University Hospital, Seoul, South Korea, 7Severance Hospital, Seoul, South Korea, 8Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea

PSY12

BASELINE CHARACTERISTICS AND PRE–INDEX TOTAL HEALTH CARE AND RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING GOLIMUMAB THERAPY

 

Carter C1, Tandon N1, Smith D2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2IMS Health Incorporated, Watertown, MA, USA

PSY13

THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES: ANALYSIS FROM A COMMERCIAL CLAIMS DATABASE

 

Padula WV, Nair KV
University of Colorado Health Sciences Center, Aurora, CO, USA

PSY14

ECONOMIC IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS TAKING OPIOID ANALGESICS

 

Summers KH1, Ohsfeldt R2, Puenpatom RA1, Rajan N1, Ben-Joseph R1
1Endo Pharmaceuticals, Inc., Chadds Ford, PA, USA, 2Texas A&M Health Science Center, College Station, TX, USA

PSY15

COSTS OF CARE FOR PRIVATELY INSURED MALES WITH HEMOPHILIA IN THE UNITED STATES, 2008

 

Guh S1, Grosse S1, McAlister S1, Kessler CM2, Soucie M1
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2Georgetown University, Washington, DC, USA

PSY16

PROJECTING THE LIFETIME ECONOMIC COSTS OF OBESITY: A BMI TRAJECTORY-BASED MODEL

 

Wang BCM1, Garrison L1, Alfonso-Cristancho R1, Wong E2, Flum D1, Arterburn D3, Sullivan SD1
1University of Washington, Seattle, WA, USA, 2Department of Veterans Affairs, Seattle, WA, USA, 3Group Health Research Institute, Seattle, WA, USA

PSY17

A PHARMACOECONOMIC EVALUATION OF ROMIPLOSTIM (NPLATE®) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN MEXICO

 

Arocho R1, Northridge K2, Rivera Hurtado R3, García Chávez J4
1Amgen, Inc., Barcelona, Spain, 2Outcomes Insights, Inc., Westlake Village, CA, USA, 3Amgen Mexico, Mexico City, Mexico, 4Mexican Institute for Social Security (IMSS), Mexico City, Mexico

PSY18

A DECISION ANALYSIS MODEL EXPLORING THE RESULTS OF A PHASE II TRIAL OF ELTROMBOPAG FOR PATIENTS WITH CHRONIC HEPATITIS C, CIRRHOSIS AND THROMBOCYTOPENIA

 

Schelfhout J, Kauf T
University of Florida, Gainesville, FL, USA

PSY19

THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

 

Wang ST1, Huang H2, Ba-mancini A2, Shi H2, Chen K1, Korves C1, Dhawan R3, Cakana A4, van de Velde H5, Duh MS1
1Analysis Group, Inc., Boston, MA, USA, 2Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, 3Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, 4Janssen-Cilag Pty Ltd, Saunderton, High Wycombe, UK, 5Johnson & Johnson ORD, Beerse, Belgium

PSY20

ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS

 

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Muciño-Ortega E3, Mould-Quevedo JF4, Galindo-Suarez RM3
1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, Mexico City, Mexico, 4Pfizer, New York, NY, USA

PSY21

COST-EFFECTIVENESS ANALISYS OF TREATMENT WITH AMFEPRAMONE (DIETHYLPROPION) IN OBESITY IN MEXICO

 

Ramirez Ramirez M1, Soto-Molina H1, Rizzoli-Cordoba A2, Delgado-Ginebra I3, Pizarro-Castellanos M2
1Iteliness Consulting, Mexico City, Mexico, 2Hospital Infantil de México Federico Gómez, Mexico City, Mexico, 3Panamerican University, Mexico City, Mexico

PSY22

ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

 

Zinzani PL1, Connors JM2, Knight AD3, Crowe AM3, Jones R4, Tucker B5
1University of Bologna, Bologna, Italy, 2BCCA Centre for Lymphoid Cancer, Vancouver, BC, Canada, 3Corvus Communications Limited, Buxted, UK, 4Genzyme Transplant and Oncology, Oxford, UK, 5Genzyme Oncology, San Antonio, TX, USA

PSY23

ECONOMIC EVALUATION OF ERYTHROPOIESIS STIMULATING AGENTS IN CRITICALLY ILL TRAUMA PATIENTS

 

Chui BKY, Hazel M, Dong J, Klarenbach S
University of Alberta, Edmonton, AB, Canada

PSY24

COST-UTILITY ANALYSES OF DIFFERENT ERYTROPOIETINS IN ANEMIC PATIENTS ON DIALYSIS IN RUSSIA

 

Vorobyev P1, Bezmelnitsyna L1, Borisenko O1, Eliseeva E2, Baev V3, Vezikova N4
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Vladivostok State Medical University, Vladivostok, Russia, 3Abakan City Hospital, Abakan, Russia, 4Petrozavodsk State University, Faculty of Medicine, Petrozavodsk, Russia

PSY25

RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

 

Naim A1, DiBonaventura M2, Lofland J1, Freedman D3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Princeton, NJ, USA

PSY26

IMPACT OF HYPONATREMIA ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS

 

Deitelzweig S1, Amin A2, Lin J3, Belk K4, Baumer D4, Lowe T5
1Ochsner Health System, New Orleans, LA, USA, 2University of California, Irvine, Irvine, CA, USA, 3Novosys Health, Flemington, NJ, USA, 4Premier, Inc., Charlotte, NC, USA, 5Premier Healthcare Alliance, Charlotte, NC, USA

PSY27

REAL-WORLD EVALUATION OF HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (PDPN) TREATED WITH PREGABALIN OR GABAPENTIN

 

Udall M, Mardekian J, Harnett J
Pfizer, Inc., New York, NY, USA

PSY28

FACTORS LEADING TO HIGH HEALTH CARE EXPENDITURE AMONG OBESE INDIVIDUALS IN UNITED STATES

 

Patel JG, Aparasu RR, Rajan SS, Johnson ML
University of Houston, Houston, TX, USA

PSY29

A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS

 

Rubino M1, Summers KH1, Ohsfeldt R2, Ben-Joseph R1, Puenpatom RA1
1Endo Pharmaceuticals, Inc., Chadds Ford, PA, USA, 2Texas A&M Health Science Center, College Station, TX, USA

Systemic Disorders/Conditions – Patient-Reported Outcomes & Preference-Based Studies

PSY30

A REAL-WORLD EVALUATION OF ADHERENCE AND PERSISTENCE OF WEIGHT-LOSS PHARMACOTHERAPY IN THE UNITED STATES: 2007-2010

 

Charland SL, Agatep BC, Aubert RE, Lazzaro J, Stanek EJ
Medco Research Institute, Medco Health Solutions, Inc, Bethesda, MD, USA

PSY31

HEMOPHILIA A: PATIENT IMPACT AND ECONOMIC BURDEN OF THE DISEASE

 

Strandberg-Larsen M1, Gater A2, Thomson A2
1Novo Nordisk, Inc., Søborg, Denmark, 2MAPI Values, Bollington, Cheshire, UK

PSY32

HOW DO MINIMALLY IMPORTANT DIFFERENCES VALUE OUTCOMES?

 

Suh JK, Doctor J
USC School of Pharmacy, Los Angeles, CA, USA

PSY33

EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN PATIENTS WITH FIBROMYALGIA

 

Schilling S1, Blum SI2, Tourkodimitris S2, Williams DA1
1University of Michigan, Ann Arbor, MI, USA, 2Forest Research Institute, Jersey City, NJ, USA

PSY34

CALCULATING PROMIS FATIGUE ITEM BANK IRT PARAMETER ESTIMATES SPECIFIC TO PATIENTS WITH FIBROMYALGIA

 

Schilling S1, Blum SI2, Tourkodimitris S2, Williams DA1
1University of Michigan, Ann Arbor, MI, USA, 2Forest Research Institute, Jersey City, NJ, USA

PSY35

VALIDATION OF THE LUPUS IMPACT TRACKER

 

Jolly M1, Kosinski M2, Garris CP3, Jhingran PM3, Mikolaitis RA1, Dennis G4, Wallace DJ5, Clarke A6, Parke A7, Dooley MA8, Strand V9, Alarcón GS10
1Rush University, Chicago, IL, USA, 2QualityMetric Incorporated, Lincoln, RI, USA, 3GlaxoSmithKline R&D, Research Triangle Park, NC, USA, 4Human Genome Sciences, Rockville, MD, USA, 5UCLA, West Hollywood, CA, USA, 6McGill University, Montreal, QC, Canada, 7University of Connecticut Health Center, at St. Francis Hospital and Medical Center, Hartford, CT, USA, 8University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 9Stanford University, Portola Valley, CA, USA, 10University of Alabama at Birmingham, Birmingham, AL, USA

PSY36

DEVELOPMENT OF THE LUPUS IMPACT TRACKER: A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

 

Jolly M1, Kosinski M2, Garris CP3, Jhingran PM3, Mikolaitis RA1, Dennis G4, Wallace DJ5, Clarke A6, Parke A7, Dooley MA8, Strand V9, Alarcón GS10
1Rush University, Chicago, IL, USA, 2QualityMetric Incorporated, Lincoln, RI, USA, 3GlaxoSmithKline R&D, Research Triangle Park, NC, USA, 4Human Genome Sciences, Rockville, MD, USA, 5UCLA, West Hollywood, CA, USA, 6McGill University, Montreal, QC, Canada, 7University of Connecticut Health Center, at St. Francis Hospital and Medical Center, Hartford, CT, USA, 8University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 9Stanford University, Portola Valley, CA, USA, 10University of Alabama at Birmingham, Birmingham, AL, USA

PSY37

THE PAIN MANAGEMENT IS ALWAYS A PUBLIC HEALTH CHALLENGE

 

Bertin P1, Rahhali N2, Auges M2, Taieb C2
1Comité LUtte contre la Douleur, Limoges, France, 2PFSA, Boulogne Billancourt, France

PSY38

PATIENT-REPORTED OUTCOMES IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY: PAIN DESCRIPTION AND QUALITY OF LIFE

 

Ko KS1, Cha BY2, Kim CH3, Kwon HS2, Lee JH4, Park TS5, Won JC1, Ko SK6, Park HJ6
1Inje University Sanggye Paik-Hospital, Seoul, South Korea, 2The Catholic University of Korea, St. Mary's Hospital, Seoul, South Korea, 3Sejong General Hospital, Bucheon-Si, Gyeonggi-do, South Korea, 4Daegu Catholic University Medical Center, Daegu-City, South Korea, 5Chonbuk National University Hospital, Jeonju Si, Jeollabuk-Do, South Korea, 6Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea

PSY39

EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN KAZAKHSTAN: PATIENT-REPORTED DATA

 

Vorobyev P1, Borisenko O1, Zhulyov Y2, Rybalova T3, Krasnova L4, Bezmelnitsyna L1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Russia Hemophilia Society, Moscow, Russia, 3Kazakhstan Hemophilia Society, Almaty, Kazakhstan, 4Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PSY40

EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN UKRAINE: PATIENT-REPORTED DATA

 

Vorobyev P1, Borisenko O1, Zhulyov Y2, Krasnova L3, Bezmelnitsyna L1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Russia Hemophilia Society, Moscow, Russia, 3Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PSY41

HEALTH-RELATED QUALITY OF LIFE IN KAZAKHSTAN PATIENTS WITH HEREDITARY COAGULOPATHIES

 

Vorobyev P1, Borisenko O1, Zhulyov Y2, Rybalova T3, Krasnova L4, Bezmelnitsyna L1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Russia Hemophilia Society, Moscow, Russia, 3Kazakhstan Hemophilia Society, Almaty, Kazakhstan, 4Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PSY42

EPIDEMIOLOGY AND QALITY OF LIFE OF ANEMIC PATIENTS ON DIALYSIS IN RUSSIA: PATIENT-REPORTED DATA

 

Vorobyev P1, Bezmelnitsyna L1, Borisenko O1, Eliseeva E2, Baev V3, Vezikova N4
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Vladivostok State Medical University, Vladivostok, Russia, 3Abakan City Hospital, Abakan, Russia, 4Petrozavodsk State University, Faculty of Medicine, Petrozavodsk, Russia

PSY43

HEALTH-RELATED QUALITY OF LIFE IN UKRAINE PATIENTS WITH HEREDITARY COAGULOPATHIES

 

Vorobyev P1, Borisenko O1, Zhulyov Y2, Krasnova L3, Bezmelnitsyna L1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Russia Hemophilia Society, Moscow, Russia, 3Moscow State Medical University named after I.M.Sechenov, Moscow, Russia

PSY44

PAIN MANAGEMENT: IMPACT ON QUALITY OF LIFE

 

Bertin P1, Rahhali N2, Auges M2, Taieb C2
1Comité LUtte contre la Douleur, Limoges, France, 2PFSA, Boulogne Billancourt, France

PSY45

CHARACTERISTICS OF CAREGIVERS AND THEIR EXPERIENCE ASSOCIATED WITH CONGENITAL HEMOPHILIA OF INHIBITOR PATIENTS

 

Wisniewski T1, Petrilla AA2, DeKoeven M2, Lee WC2, Cooper DL1, Holot N1, von Mackensen S3
1Novo Nordisk, Inc., Princeton, NJ, USA, 2IMS Health, Falls Church, VA, USA, 3University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

PSY46

DISEASE SYMPTOMS, TREATMENT SATISFACTION, AND COPING STRATEGIES IN PATIENTS WITH LUPUS

 

Lerstrøm K1, Crimmings M2, Govoni M3, Nikaï E3, Merrill J4, Isenberg D5
1Lupus Europe, Romford, UK, 2Lupus Foundation of America, Washington, DC, USA, 3UCB, Brussels, Belgium, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, 5University College London Hospitals, London, UK

PSY47

WILLINGNESS TO PAY (WTP) FOR WEIGHT LOSS COACHING: RESULTS FROM THE POWER TRIAL

 

Alavi R1, Appel L1, Brancati F1, Clark J1, Mohr P2, Daumit G1
1Johns Hopkins University, Baltimore, MD, USA, 2Center for Medical Technology and Policy, Baltimore, MD, USA

Systemic Disorders/Conditions – Health Care Use & Policy Studies

PSY48

A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA)

 

Tarride JE1, Harrington K2, Balfour R3, Simpson P4, Foord L5, Anderson L6, Lakey WK7
1McMaster University, Hamilton, ON, Canada, 2Abbott Canada, St Laurent, QC, Canada, 3Pacific Blue Cross, Vancouver, BC, Canada, 4GlaxoSmithKline, Mississauga, ON, Canada, 5AstraZeneca, Mississauga, ON, Canada, 6British Columbia Public Service Agency, Victoria, BC, Canada, 7British Columbia Public Service Agency, Vancouver, BC, Canada

PSY49

PREDICTORS OF OBESITY TREATMENT (COUNSELING OR PHARMACOTHERAPY) IN AMBULATORY SETTINGS

 

Mehta HB, Patel J, Parikh R, Abughosh S
University of Houston, Houston, TX, USA

PSY50

PRESCRIPTION MONITORING PROGRAMS' UTILIZATION

 

Fleming ML, Barner JC, Chandwani H, Okoro T, Weber S
University of Texas at Austin, Austin, TX, USA

PSY51

EFFECTIVENESS OF FDA'S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF LIVER DAMAGE

 

Goyal RK1, Rajan SS2, Essien EJ2, Sansgiry S2
1University of North Carolina, Chapel Hill, NC, USA, 2University of Houston, Houston, TX, USA

PSY52

POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) WITH PAIN MEDICATIONS AMONG PATIENTS WITH BACK AND NECK PAIN DIAGNOSES CATEGORIZED INTO NOCICEPTIVE, NEUROPATHIC OR MIXED PAIN COHORTS

 

Kozma C1, Benson C2, Patel A2, Provenzano D3, Slaton T4, Biondi D2, Kim M2
1Independent Research Consultant/Adjunct Professor, University of South Carolina, St. Helena Island, SC, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 3Ohio Valley General Hospital, Pittsburgh, PA, USA, 4TLS Stats, West Columbia, SC, USA

PSY53

WITHDRAWN

 

 

PSY54

APPLICATION OF THE NON-LINEAR BLINDER-OAXACA DECOMPOSITION TO STUDY RACIAL/ETHNIC DISPARITIES IN ANTI-OBESITY MEDICATION USE

 

Mehta HB, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA

PSY55

NATIONAL TRENDS IN ANTI-OBESITY MEDICATION USE FROM 2002 TO 2007

 

Mehta HB, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA

PSY56

CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION DRUG MONITORING PROGRAMS

 

Talbert J, Perin N, Blumenschein K, Freeman PR
University of Kentucky, Lexington, KY, USA

PSY57

DOES CLINICAL DIAGNOSIS OF OBESITY INCREASE THE LIKELIHOOD OF RECEIVING OBESITY RELATED COUNSELING? A 2005-2008 NAMCS-NHAMCS ANALYSIS

 

Kadakia A, Mehta H, Rajan SS, Abughosh S
University of Houston, Houston, TX, USA

PSY58

DISPARITY IN OBESITY MANAGEMENT: UNDER-TREATMENT AMONG ELDERLY POPULATION

 

Shah AJ, Patel JG, Rajan SS, Abughosh S, Masilamani S
University of Houston, Houston, TX, USA

PSY59

IMPACT OF OBESITY ON AGE-SPECIFIC PREVALENCE OF CHRONIC DISEASES IN THE UNITED STATES

 

Patel JG, Shah A, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA

PSY60

ECONOMIC CONSEQUENCES OF UNDER-UTILIZATION WITH TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS

 

Carter C1, Gunnarsson C2, Rizzo J3, Bolge S1, Ingham M1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA

PSY61

CHARACTERISTICS OF GOLIMUMAB UTILIZATION AND COSTS IN A SPECIALTY PHARMACY PROVIDER (SPP) SETTING

 

Ellis L1, Tandon N1, Mody S1, Doshi D1, Baek C2, Gunnarsson C3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Diplomat Pharmacy, Wartz Creek, MI, USA, 3S2 Statistical Solutions, Inc., Cincinnati, OH, USA

PSY62

PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS

 

Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PSY63

LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS ACROSS 30 INFUSIONS

 

Carter C1, Haas S2, Gunnarsson C2, Rizzo J3, Ingham M1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3Stony Brook University, Stony Brook, NY, USA

PSY64

GE CENTRICITY® ELECTRONIC MEDICAL RECORDS STUDY: COMORBIDITIES AND BIOLOGIC EXPERIENCE AMONG PATIENTS RECEIVING GOLIMUMAB

 

Tandon N1, Carter C1, Haas S2, Gunnarsson C2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA

PSY65

CHARACTERISTICS OF GOLIMUMAB UTILIZATION IN A LARGE NATIONAL PAYER DATABASE

 

Tandon N1, Saulnier A2, Gunnarsson C2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA

PSY66

BIOLOGIC EXPERIENCE AND DOSING OF GOLIMUMAB PATIENTS IN MANAGED CARE

 

Carter C1, Tandon N1, Smith D2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2IMS Health Incorporated, Watertown, MA, USA

PSY67

REASONS FOR INITIATING INTRAVENOUS BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS: SUBSET ANALYSIS OF PRIOR SUBCUTANEOUS INJECTION (SQ) USERS AND IMPLICATIONS FOR SHARED DECISION MAKING

 

Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PSY68

DEFINITIONS OF ANTI-TNF DISCONTINUATION MAY IMPACT UNDERSTANDING OF REAL-WORLD UTILIZATION PATTERNS

 

Schmeichel-Mueller C1, Buysman E2, Bolge S1, Ingham M1, McKenzie RS1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2i3 Innovus, Eden Prairie, MN, USA

PSY69

MODELING THE IMPACT OF REFILL OR ADMINISTRATION GAPS ON PATIENT DRUG LEVELS OF THE TNF-ALPHA INHIBITORS ETANERCEPT AND INFLIXIMAB

 

Ingham M, Carter C, Bolge S, Comisar C
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PSY70

ASSOCIATION OF PROVIDER CONTINUITY WITH HOSPITALIZATION AMONG FLORIDA MEDICAID ENROLLEES WITH SICKLE CELL DISEASE (SCD)

 

Ma Q, Kauf T, Hall AG
University of Florida, Gainesville, FL, USA

PSY71

HEALTH AND FUNCTIONAL STATUS FOR INDIVIDUALS WITH THROMBOCYTOPENIA IN THE UNITED STATES: EVIDENCE FROM NHANES

 

Kauf T1, Schelfhout J1, Nelson DR1, Wang PF2
1University of Florida, Gainesville, FL, USA, 2GlaxoSmithKline, Philadelpha, PA, USA

PSY72

VARIATION BY AGE IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS INITIATING TREATMENT FOR MYELODYSPLASTIC SYNDROMES

 

Pashos C1, Grinblatt DL2, Komrokji RS3, Sekeres MA4, Narang M5, Sullivan KA6, Street TK7, Khan ZM7
1United BioSource Corporation, Lexington, MA, USA, 2NorthShore University Health System, Evanston, IL, USA, 3Moffitt Cancer Center, Tampa , FL, USA, 4Cleveland Clinic, Cleveland , OH, USA, 5Alliance Hematology Oncology, Westminster, MD, USA, 6Celgene Corporation, Overland Park, KS, USA, 7Celgene Corporation, Summit, NJ, USA

PSY73

PAIN MEDICATION USE AND DETERMINANTS OF OPIOIDS PRESCRIBING IN THE UNITED STATES OUTPATIENT SETTINGS

 

Rasu R, Sohraby R, Cunningham L, Malewski D, Knell M
University of Missouri-Kansas City, Kansas City, MO, USA

PSY74

TREATMENT CHOICE FOR PAIN MANAGEMENT IN NURSING HOME HOSPICE/PALLIATIVE CARE RESIDENTS IN THE USA

 

Agrawal R, Mhatre SK, Sansgiry S
University of Houston, Houston, TX, USA

Systemic Disorders/Conditions – Research on Methods

PSY75

PREVALENCE RATIOS AGAINST ODDS RATIOS AS EFFECT MEASURES IN A CROSS-SECTIONAL STUDY OF OBESITY AND ITS CHRONIC COMORBID CONDITIONS

 

Patel JG, Rajan SS, Aparasu RR, Johnson M
University of Houston, Houston, TX, USA

PSY76

TREATMENT OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) KNOWLEDGE STUDY (TOCKS): NOVEL DATA COLLECTION, VIEWING AND DYNAMIC REPORTING MECHANISM

 

Arnold RJ1, Groesser K2
1Mount Sinai School of Medicine, New York, NY, USA, 2Arnold Consultancy & Technology LLC, New York, NY, USA

PSY77

COMPARISON OF OBESITY-ASSOCIATED COMORBIDITIES BETWEEN EMR AND CLAIMS DATABASES

 

Brixner D1, Bron M2, Bellows BK1, Ye X1, Harikrishnan V2, Oderda G1
1University of Utah, Salt Lake City, UT, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA

PSY78

ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL POLYNOMIALS

 

Wong E1, Wang BCM2, Garrison L2, Alfonso-Cristancho R2, Flum D2, Arterburn D3, Sullivan SD2
1Department of Veterans Affairs, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Group Health Research Institute, Seattle, WA, USA

PSY79

CONTENT VALIDITY OF THE MULTIPLE SCLEROSIS INTERNATIONAL QOL (MUSIQOL) QUESTIONNAIRE IN IRAN, EGYPT, MOROCCO, SAUDI ARABIA AND TUNISIA

 

Trevin A1, Salmassi L1, Auquier P2
1MAPI Institute, Lyon, France, 2Timone University Hospital, Marseille, France

PSY80

PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

 

Mühlbacher A1, Bridges JF2, Bethge S1, Dintsios CM3, Schwalm A3, Nübling M4
1Duke University, Durham, NC, USA, 2Johns Hopkins University, Baltimore, MD, USA, 3Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 4Gesellschaft für empirische Beratung mbH, Denzlingen, Germany

PSY81

PERCEPTIONS ABOUT 'RAPID' WARFARIN REVERSAL WITH FRESH FROZEN PLASMA TO REDUCE THE INR: A NOVEL SURVEY METHODOLOGY

 

Petrozzino J1, Hoesche J2, Jones C2
1Compara Biomedical, Orlando, FL, USA, 2CSL Behring, King of Prussia, PA, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 23, 2011 - 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 23, 2011 - 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 23, 2011 - 6:30PM – 7:30PM
DISMANTLE: Monday, May 23, 2011 - 8:30PM – 9:00PM

Urinary/Kidney Disorders – Clinical Outcomes Studies

PUK1

INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

 

Rubin JL1, Li S2, Yu H3, Dunning S2, Sato R3
1DaVita Clinical Research, Minneapolis, MN, USA, 2Chronic Disease Research Group, Minneapolis, MN, USA, 3Pfizer, Collegeville, PA, USA

PUK2

DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

 

Park T, Shamliyan TA
University of Minnesota, Minneapolis, MN, USA

PUK3

DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

 

Alhammad AM, Al Hawaj MA, Alsalman AJ, Alhashem YN, Harpe SE, Smith WR, Brophy DF
Virginia Commonwealth University, Richmond, VA, USA

PUK4

CUMULATIVE EXPOSURE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)

 

Yarger S1, Nwokeji E1, Trice S2, Chao S3, Devine J2, Potyk R2, Gutke G4, Bonnema A3
1Department of Defense/GDIT, Fort Sam Houston, TX, USA, 2Department of Defense, Fort Sam Houston, TX, USA, 3Air Force Medical Support Agency, San Antonio, TX, USA, 4Healthcare Informatics Division, San Antonio, TX, USA

PUK5

TREATMENT PATTERNS IN OVERACTIVE BLADDER: REAL-WORLD PATIENT POPULATION

 

Ellsworth P1, Bavendam T2, Zou KH2, Mastey V2, Chen CI2
1Brown University, Providence, RI, USA, 2Pfizer, Inc., New York, NY, USA

PUK6

LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

 

Burke N1, Tarride JE1, Bowen J1, von Keyserlingk C2, Lim W1, Crowther M1, Goeree R1
1McMaster University, Hamilton, ON, Canada, 2Programs for Assessment of Technology in Health (PATH) Research Institue, Hamilton, ON, Canada

Urinary/Kidney Disorders – Cost Studies

PUK7

ECONOMIC EVALUATION OF CINACALCET VERSUS STANDARD TREATMENT IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN MEXICO

 

Arocho R1, Ianazzo S2, Rivera Hurtado R3, Paniagua Sierra JR4
1Amgen, Inc., Barcelona, Spain, 2AdRes Health Economics & Outcomes Research, Torino, Italy, 3Amgen Mexico, Mexico City, Mexico, 4Mexican Institute for Social Security (IMSS), Mexico City, Mexico

PUK8

KIT73 STUDY: DOES TYPE OF DONOR INFLUENCE LONG-TERM COSTS OF CARE? RESULTS FROM POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

 

Tedesco-Silva HJ1, Manfro RC2, Asano E3, Nita ME3, Barbosa E3, Carvalho JF3, Szabo SM4, Levy AR4, Donato BM5, Rahal E3, The KIT73 Study Grou P3
1Fundação Oswaldo Ramos - Hospital do Rim e Hipertensão, São Paulo, SP, Brazil, 2Hospital de Clínicas de Porto Alegre, São Paulo, SP, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 4Oxford Outcomes Ltd., Vancouver, BC, Canada, 5Bristol-Myers Squibb, Wallingford, CT, USA

PUK9

MEDICAL CARE SPENDING ASSOCIATED WITH CHRONIC KIDNEY DISEASE BY STAGE OF DISEASE: A POPULATION-BASED STUDY

 

Taylor TN1, Salinitri FD2, Satterthwaite DW1
1Wayne State University, Detroit, MI, USA, 2Wayne State University, Oakwood Hospital and Medical Center, Detroit, MI, USA

PUK10

KIT73 STUDY: RELATIONSHIP BETWEEN COSTS OF CARE AND 12-MONTH GLOMERULAR FILTRATION RATES IN POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

 

David-Neto E1, Esmeraldo RM2, Asano E3, Nita ME3, Nishikawa AM3, Barbosa E3, Szabo SM4, Levy AR4, Carvalho JF3, Donato BM5, Rahal E3, The KIT73 Study Grou P3
1Hospital das Clínicas da Faculdade de Medicina da USP, HCFMUSP, São Paulo, SP, Brazil, 2Hospital Geral de Fortaleza, Fortaleza, Ceara, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 4Oxford Outcomes Ltd., Vancouver, BC, Canada, 5Bristol-Myers Squibb, Wallingford, CT, USA

PUK11

UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE

 

Lee R1, Snedecor SJ2, Kvasz MG3, Trocio J4, Borgman B5
1Weill Medical College of Cornell University, New York, NY, USA, 2Pharmerit North America, LLC, Bethesda, MD, USA, 3Pfizer, Paris, France, 4Pfizer, Inc., New York, NY, USA, 5Pfizer Sweden, Sollentuna, Sweden

PUK12

COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS

 

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Camacho-Cordero L2, Muciño-Ortega E3, Mould-Quevedo JF4, Galindo-Suarez RM3
1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, Mexico City, Mexico, 4Pfizer, New York, NY, USA

PUK13

COST-EFFECTIVENESS ANALYSIS OF THE EARLY CONVERSION OF TACROLIMUS TO MTOR INHIBITORS IN PATIENTS WITH RENAL TRANSPLANTATION

 

Gamboa O1, Montero C2, Mesa L3, Benavides C4, Reino A5, Castillo JS6
1Fundación Esensa, Bogotá, Colombia, 2Clinica Universitaria Colombia, Bogotá, Colombia, 3Fundacion Valle de Lili, Cali, Colombia, 4Fundación CardioInfantil, Bogotá, Colombia, 5Hospital San Vicente de Paul, Medellín, Colombia, 6Instituto de la Evaluacion de la Calidad y Atención en salud (IECAS), Bogotá, Colombia

PUK14

A MARKOV MODEL COMPARING SACRAL NEUROMODULATION AND BOTULINUM TOXIN-A FOR MEDICARE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER REFRACTORY TO CONSERVATIVE CARE

 

Ganz M1, Clemens JQ2, Anger J3, Denevich S1, Shah D1, Carlson A4, Wittek MR5, Pashos C1
1United BioSource Corporation, Lexington, MA, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Cedars-Sinai Medical Center, Beverly Hills, CA, USA, 4Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, 5Medtronic, Inc., Minneapolis, MN, USA

PUK15

THE COST-EFFECTIVENESS OF LANTHANUM CARBONATE IN THE TREATMENT OF HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS FROM A CANADIAN PERSPECTIVE

 

Vegter S1, Tolley K2, Levin A3, Lok CE4, Morton AR5, Soroka SD6, Keith MS7, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Tolley Health Economics, Buxton, UK, 3St Paul's Hospital, Vancouver, BC, Canada, 4University of Toronto, Toronto, ON, Canada, 5Queen's University, Kingston General Hospital, Kingston, ON, Canada, 6Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada, 7Shire Pharmaceuticals, Wayne, PA, USA

PUK16

COST-EFFECTIVENESS OF VALGANCICLOVIR 200 DAYS PROPHYLAXIS VERSUS 100 DAYS PROPHYLAXIS IN KIDNEY TRANSPLANT PATIENTS AT HIGH-RISK FOR DEVELOPING CYTOMEGALOVIRUS DISEASE

 

Vicente C1, Humar A2, Lemieux C3, Zilbershtein R1, Douglas P4, Formica L4, Piwko C1
1PIVINA Consulting Inc., Thornhill, ON, Canada, 2University of Alberta, Edmonton, ON, Canada, 3Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 4Hoffmann-La Roche Limited, Mississauga, ON, Canada

PUK17

UTILIZATION AND ECONOMIC IMPACT OF IV IRON AND ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS: A MULTI-HOSPITAL STUDY

 

Joshi AD, Holdford D, Brophy D, Harpe SE
Virginia Commonwealth University, Richmond, VA, USA

Urinary/Kidney Disorders – Patient-Reported Outcomes & Preference-Based Studies

PUK18

THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL): DEVELOPMENT OF A CONCEPTUAL FRAMEWORK

 

Cole JC1, Krasa HB2, Cheng R1, Oberdhan D2, Urwongse J3, Schaefer C3, Czerwiec F2
1Covance Market Access Services, Inc., San Diego, CA, USA, 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, 3Covance Market Access Services, Inc., Gaithersburg, MD, USA

Urinary/Kidney Disorders – Health Care Use & Policy Studies

PUK19

KIT73: PRELIMINARY REPORTS OF IMMUNOSUPRESSANT THERAPY PATTERNS IN A COHORT OF POST KIDNEY TRANSPLANT PATIENTS IN BRAZIL

 

Carvalho DDBM1, Garcia V2, Abbud-Filho M3, Nishikawa AM4, Asano E4, Nita ME4, Szabo SM5, Levy AR5, Carvalho JF4, Donato BM6, Rahal E4, The KIT73 Study Grou P4
1Hospital Geral Bonsucesso, Rio de Janeiro, Brazil, 2Universidade Federal de Ciências da Saúde de Porto Alegre, UFCSPA, Porto Alegre, Brazil, 3Complexo Hospitalar Santa Casa de Porto Alegre, São Jose do Rio Preto, SP, Brazil, 4Bristol-Myers Squibb S/A, São Paulo, SP, Brazil, 5Oxford Outcomes Ltd., Vancouver, BC, Canada, 6Bristol-Myers Squibb, Wallingford, CT, USA

PUK20

EARLY DETECTION, SCREENING, AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG ACTIVELY EMPLOYED – AN INTEGRATED POPULATION HEALTH MANAGEMENT APPROACH

 

Harshman R1, Naim A2, Carter J1, Richerson G1, Nair KV3
1Southern Company/Georgia Power, Atlanta, GA, USA, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3University of Colorado, Aurora, CO, USA

PUK21

PATIENT CHARACTERISTICS ASSOCIATED WITH INITIATION OF OVERACTIVE BLADDER (OAB) DISCUSSION WITH A PHYSICIAN

 

Botros S1, Chen CI2, Bavendam T2, Zou KH2, Goren A3, Gupta S4
1NorthShore Medical Group, Evanston, IL, USA, 2Pfizer, Inc., New York, NY, USA, 3Kantar Health, New York, NY, USA, 4Kantar Health, Princeton, NJ, USA

Urinary/Kidney Disorders – Research on Methods

PUK22

LEVELING THE PLAYING FIELD: A CASE STUDY ON TECHNICAL PRECISION IN COMPARATIVE EFFECTIVENESS RESEARCH FOR CLINICALLY LOCALIZED PROSTATE CANCER (PC)

 

Hughes KE1, Duff SB2, Husain N1, Cooperberg MR3
1Avalere Health LLC, Washington, DC, USA, 2Veritas Health Economics Consulting, Carlsbad, CA, USA, 3University of California, San Francisco, San Francisco, CA, USA

PUK23

METHODOLOGICAL CONSIDERATIONS FOR COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY

 

Globe D1, Carlson J2, Patel H3, Colayco D1, Hansen RN2, Watanabe J2, Sullivan SD2
1Allergan LLC, Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3Allergan, LLC, Marlow Buckinghamshire, UK

PUK24

USE OF BIOMARKERS IN PROPENSITY SCORE MATCHING TO MITIGATE CHANNELING BIAS IN A RETROSPECTIVE COHORT OF ESRD PATIENTS

 

Wilson SM, Rubin JL
DaVita Clinical Research, Minneapolis, MN, USA



16th Annual International Meeting Main Page